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Abstract 
 
Shp2 (Src Homology 2 Domain-containing Protein Tyrosine Phosphatase 2) is a pivotal 
player in various signaling pathways in response to growth factors. It contains two SH2 
domains (N-SH2 and C-SH2), a phosphatase catalytic domain and a C-terminal tail 
containing two tyrosyl phosphorylation sites. While the tyrosine phosphorylation of C-
terminal tail has been shown to be critical for the proper Shp2 functions, there is a lack of 
understanding on how the phosphorylation of these two tyrosine sites regulates the 
conformational changes and functions of Shp2. Here, we developed a FRET-based Shp2 
reporter, a single molecule comprised of the full length human Shp2 concatenated in 
between a FRET pair, ECFP and YPet.  
 
In vitro incubation of Shp2 reporter with PDGFRβ induced a significant FRET increase 
via intramolecular interaction between C-SH2 and phosphotyrosine 580 (pY580). The 
phosphotyrosine 542 (pY542) has an adverse position despite a favored surrounding 
amino acid sequence such that it can only bind to C-SH2 in the absence of pY580. In 
contrast, pY542 dominates the binding of C-SH2 in mouse embryonic fibroblasts 
(MEFs). This intramolecular binding is essential for the subsequent effective 
phosphorylation of Y580, which is then sequestered by Grb2 in cells. These results 
suggested that the cellular environment can tune and switch the interaction of C-SH2 
toward pY542. When the sequences containing Y542 and Y580 were engineered to 
exchange their positions such that the favored sequence containing Y542 is located at the 
advantageous position of 580 (Y542’), pY542’ constitutively dominates the binding of C-
SH2 both in vitro and in MEFs. This rewiring of intramolecular interactions within Shp2 
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also caused a reprogramming of downstream signaling events, resulting in a more 
transient ERK phosphorylation. Therefore, our results indicate that the combination of a 
favorable sequence with an adverse position can create a delicate balance and plasticity 
of intramolecular interactions, which can determine the downstream cellular 
signaling/functions, and may represent a general design principle for functional 
molecular units tunable by environmental inputs.   
 
In addition to the intramolecular interactions we discovered, we also investigate the effect 
of these interactions on Shp2 phosphatase activity. We found that intramolecular binding 
between C-SH2 and pY580 doesn’t change Shp2 activity while the binding between C-
SH2 and pY542 increases Shp2 activity using phosphatase activity assay. Moreover, 
phosphatase activity assay also showed that N-SH2 domain can also interact 
intramolecularly with pY542 or pY580 when C-SH2 is mutated and these interactions 
increase phosphatase activity. Our FRET reporter also enables us to visualize 
autodephosphorylation process in vitro. The results with the phosphatase inhibitors and 
inactive phosphatase mutants showed us that phosphatase activity is not necessary for 
intramolecular interactions. Even though phosphatase domain doesn’t play a direct role in 
the intramolecular interactions between SH2 domains and C-tail phosphotyrosines, it can 
control the level of the phosphotyrosines through its phosphatase activity therefore affect 
the intramolecular interactions.  
 
In conclusion, we have utilized FRET-based reporter to investigate the intramolecular 
interactions and activation mechanisms of Shp2. We not only showed the tunable 
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intramolecular interactions between C-SH2 and C-tail phosphotyrosines but also 
established the intrinsic design principles of Shp2 that underlies the tunability. Last but 
not least, we found the effect of these intramolecular interactions on phosphatase activity 
and downstream ERK signaling. 
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Chapter 1 
Introduction 
 
Shp2 Structure and Functions 
Protein phosphorylation  
Protein phosphorylation is one type of post-translational modifications and an important 
regulatory mechanism that occurs in both prokaryotic and eukaryotic organisms. 
Regulation of proteins by phosphorylation is one of the most common modes of 
regulation of protein functions. The Nobel Prize in Physiology or Medicine in 1992 was 
rewarded to Edmond H. Fischer and Edwin G. Krebs “for their discovery concerning 
reversible phosphorylation as a biological regulatory mechanism”. Reversible protein 
phosphorylation involves the addition/removal of a phosphate molecule to specific amino 
acid residues. The addition/removal of a negatively charged phosphate group to a residue 
can change the property of this residue and further alter the properties of the protein. The 
two reversible states of a certain protein at a specific residue form the basis for the 
regulation. Many enzymes/adapters are switched on or off by phosphorylation and 
dephosphorylation. Generally, phosphorylation modulates activities of proteins by direct 
allosteric interactions or by providing binding sites for other proteins. 
 
Tyrosine phosphorylation  
Phosphorylation can happen to different amino acid residues, such as serine, threonine 
and tyrosine in eukaryotes. Since the discovery of Src kinase more than 30 years ago, 
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tyrosine phosphorylation has emerged as a fundamentally important mechanism for 
signal transduction, which is also our focus here. Protein tyrosine kinases (PTKs) and 
protein tyrosine phosphatases (PTPs) control the tyrosine phosphorylation of molecules 
in a variety of cellular events, such as proliferation, differentiation, migration, survival 
and apoptosis. PTKs catalyze the addition of a phosphate group to tyrosine side chains in 
proteins (phosphorylation) while PTPs remove the phosphate (dephosphorylation). 
Phosphorylation of tyrosine creates the binding site for several kinds of signal 
transduction modules. The two most common ones are Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains. The interaction between phosphotyrosine and 
SH2/PTB domain can further modulate enzyme activity, protein localization and protein 
interaction/signaling complex formation that are essential components and features of 
signaling transduction. Therefore, PTKs and PTPs are important switches for many 
signaling events and determine various physiological consequences.  
 
PTKs and PTPs  
Both PTKs and PTPs can be categorized by whether they have trans-membrane domain 
or not. Receptor tyrosine kinases/phosphatases (RTKs/RTPs) generally have an 
extracellular domain, a transmembrane domain and an intracellular catalytic domain 
while non-receptor tyrosine kinases/phosphatases (NRTKs/NRTPs) are cytosolic proteins. 
Sometimes NRTKs/NRTPs can be membrane targeted via post-translational modification. 
The receptors for many growth factors, such as EGFR, PDGFR, are RTKs and plays 
crucial roles in the initiation of cell signaling cascades. The detailed description of PDGF 
signaling pathway will be introduced later. PTKs and PTPs have been implicated in 
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various diseases conditions, especially cancer, therefore are important targets for drug 
development. 
 
PTPs and Shp2  
Shp2 (Src Homology 2 Domain-containing Protein Tyrosine Phosphatase 2), also known 
as SHP-2, SHPTP2, Syp, PTP1D and PTP2C, belongs to the family of protein tyrosine 
phosphatases (PTPs). PTP family has many subclasses, one of which is called classical 
PTPs with a cysteine-based PTP domain. Shp2 is a cytoplasmic classical PTP. The SH2 
domain containing PTPs (Shps) are a subfamily of NRTP that contain SH2 domains. 
Shp2 has a close relative, Shp1 (SHP-1, PTP1C, SHPTP-1), which is structurally similar 
to Shp2. Drosophila and C. elegans also have Shp homologs called Corkscew and Ptp-2, 
respectively, suggesting the evolutionary importance of Shps. 
 
Shp2 structure and expression  
In contrast to our substantial knowledge of PTKs, the structures and functions of PTPs 
remain elusive. Among PTPs Shp2 attracts particular interest because of its distinctive 
structure and prominent functions. Shp2 has two N-terminal SH2 domains (N-SH2 and 
C-SH2), a catalytic PTP domain, and a C-terminal tail with tyrosine phosphorylation sites 
and a proline-rich motif. Unlike the restricted expression of Shp1 in hematopoietic cells, 
Shp2 is ubiquitously expressed and predominately localized in the cytoplasm [1]. Both 
SH2 domains of Shp2 can bind to phosphotyrosine sites, thus providing adaptor function, 
while the catalytic PTP domain can also bind to phosphotyrosine and catalyze 
dephosphorylation reaction. In addition, the tyrosine sites at the C-terminal tail of Shp2 
 4 
 
upon phosphorylation can interact with SH2 or PTB domains while the proline-rich 
region has the potential to bind proteins containing SH3 domains.  
 
The role of Shp2 in signaling  
The multiple signaling modules within Shp2 and its catalytic activity add up to the 
complexity of its roles in signaling transduction and its ability in participating in a variety 
of cellular responses. Ample evidence indicates the involvement of Shp2 in signaling 
events downstream of growth factors, cytokines, hormones and extracellular matrixes. 
Because of its phosphatase nature, Shp2 was first thought to be the “off” switch of 
signaling transduction as its closely relative Shp1, which attenuates signal transduction. 
However, Shp2 has been shown to be a positive regulator and necessary for signal 
propagation and amplification, particularly in the Ras-Erk pathway [2]. The exact 
mechanism of Shp2 in enhancing the Erk activation and its target substrates remain 
largely unknown. Two models of Shp2 in activating the Ras-Erk pathway have been 
proposed. One is the adaptor model and the other is the enzyme activation model. In the 
adaptor model, phosphotyrosines on the C-tail of Shp2 recruit molecules containing SH2 
or PTB domain (e.g. Grb2) and activate the downstream effectors without the 
involvement of Shp2 phosphatase activity. The enzyme activation model emphasizes the 
role of phosphatase activity and indicates that the Shp2 activity either activates a positive 
regulator or inhibits a negative one in the Ras-Erk cascade [3]. There is evidence 
supporting both models. Indeed, these models are not mutually exclusive and may be 
responsible for different conditions. 
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Shp2 activity and its regulation  
The Shp2 activity has been shown to be essential in multiple pathways and the adaptor 
model is not likely the only role Shp2 plays. The enzymatic activity of Shp2 has already 
been studied extensively by biochemists. Shp2 has a low basal phosphatase activity. 
Either the deletion of SH2 domains or the engagement of SH2 domains with 
phosphopeptides greatly increases Shp2 activity, which leads to the hypothesis that SH2 
domains inhibit phosphatase activity [4, 5]. The crystal structure of Shp2 without its C-
tail provided further evidence supporting this hypothesis. The structure showed intensive 
interaction between N-SH2 and PTP domains, which blocks the catalytic cleft and 
distorts the phosphotyrosine binding pocket of the PTP domain [6]. The phosphotyrosine 
binding pocket of N-SH2 on the other side is still accessible but slightly distorted by the 
PTP domain interaction. In contrast the C-SH2 domain has minimal interaction with the 
PTP domain and has undisturbed phosphotyrosine binding site. When N-SH2 domain 
binds to phosphorylated tyrosine ligands, it changes N-SH2 conformation and alters its 
interaction with PTP domain, and therefore releases the inhibition of phosphatase activity. 
This elegant structural study demonstrated that the N-SH2 acts like a molecular switch of 
Shp2 activity. However, the C-tail was missing in the crystal structure and hence the 
function of the C-tail was not elucidated.  
 
Shp2 binding partners and substrates  
Since its discovery more than one decade ago, Shp2 has been intensively studied in 
diverse signaling pathways and many Shp2 binding partners and substrates were 
identified. Most binding partners associate with the SH2 domains of Shp2. This includes 
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receptor tyrosine kinases (e.g. PDGFRβ, EGFR, IR, IGFR), non-receptor tyrosine kinases 
(e.g. JAK), adaptor proteins (Gab1 Gab2 IRS-1, FRS-2), transmembrane glycoproteins 
(SIRP/SHPS and PECAM-1) and extracellular matrix receptors (e.g. integrin) etc [7]. 
However, only a few proteins (e.g. Grb2, Src) were found to bind to the proline-rich 
motif of Shp2 through SH3 domain and only in vitro not in cells [8, 9]. And only Grb2 
and Grb7 were recognized to bind to phosphorylated tyrosine of Shp2 C-tail [10, 11]. 
Among the binding partners of Shp2, some were also identified as Shp2 substrates, e.g. 
PDGFRβ, IRS-1, SHPS, and Gab1. Interestingly, all the Shp2 substrate identified to date 
bind to the SH2 domains of Shp2 [12]. Shp2 itself is also a substrate that has been shown 
by trans/auto-dephosphorylation of Shp2 in vitro and in cells [13, 14]. 
 
The physiological importance of Shp2  
Shp2 and its homologues are present in both vertebrate and invertebrate. Drosophila 
homologue of Shp2, Corkscrew (Csw) is required for Torso RTK pathway, which directs 
head and tail development. Csw also has a signal enhancing role in sevenless fibroblast 
growth factor receptor and Drosophila epidermal growth factor receptor signaling 
pathways [15]. In Xenopus, Shp2 is involved in gastrulation. It participates in FGF-
induced mesoderm induction and elongation and active mutant Shp2 can bypass FGF and 
potentiate Erk activation [16]. Deletion of Shp2 in mice leads to early embryonic lethality 
suggesting its essential role in development. Shp2 null mice have defective gastrulation 
or mesodermal differentiation, similar to the phenotypes of FGFR mutant mice [17]. 
Shp2 is also involved in FGFR signaling-directed limb development and branchial-arch 
formation [18].  
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Shp2 related human diseases  
PTPs regulate multiple cancer-associated signaling processes that control cell 
proliferation, adhesion and migration. Some PTPs have been identified as tumor-
suppressor gene but PTPN11 encoding Shp2 is believed to be a proto-oncogene. 
Germline PTPN11 mutations have been identified in about 50% of cases of Noonan 
syndrome (NS) [19] and almost all cases of LEOPARD syndrome (LS) [20]. NS is a 
fairly common (stated incidence 1:1000–1:2500 live births) autosomal dominant 
developmental disorder characterized by short stature, facial abnormalities and congenital 
heart defects and associated with an increased risk of developing leukemia. LS is a much 
rarer disorder which shares multiple features with NS and might also be associated with a 
cancer predisposition. In addition, somatic PTPN11 mutations were discovered in about 
35% cases of sporadic juvenile myelomonocytic leukemia (JMML) [21]. PTPN11 
mutations have been detected at low frequency in some solid human tumors, including 
lung and colon cancer, neuroblastoma and melanoma [22].  
 
Shp2 activity and its relation to diseases  
The majority of the mutations are missense mutations resulting in single amino-acid 
changes affecting residues in the N-SH2 or PTP domains. These two domains were 
shown by crystal structure to be involved in autoinhibition of the basal activity. The 
mutations released the autoinhibitiion and increased basal activity. The degree of activity 
of the mutations can be correlated to the severity of the diseases. Generally, mutations 
with low level of Shp2 activation cause NS whereas mutations with higher level Shp2 
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activation cause cancer [22]. Noticeably, the relationship between the molecular 
properties and pathogenic spectrum of Shp2 mutations is more complicated than 
described above. The molecular properties of a particular mutant that can predict whether 
it is potentially oncogenic are not clear. Interestingly, LEOPARD syndrome-associated 
PTPN11 mutations are catalytically inactive even though the features of LS are very 
similar to NS. How gain- and loss- of function Shp2 mutants can have similar phenotypes 
(NS and LS) is very intriguing and need to be further investigated [22, 23].  
 
Shp2 and cancer  
The major Shp2-associated cancer is JMML, which is characterized by invasive myeloid 
lineage cells and increased production of fetal hemoglobin [21]. JMML has been 
indicated to be a disease of excessive Ras activation in hematopoietic cells [24] 
Molecular and biochemical studies showed that both SH2 domains must retain their 
phosphotyrosine binding abilities to promote myeloid transformation. PTP activity and 
one of the C-terminal tyrosine (Y542) are also essential for the transformation while the 
other tyrosine Y580 has less contribution. Therefore, the increased basal activity of Shp2 
alone is not sufficient to induce hematological disease. The targeting of Shp2 to the 
appropriate subcellular location through its SH2 domains as well as C-terminal tyrosines 
is necessary for JMML to occur [25]  
 
Shp2 and pathogens  
Shp2 is also linked to gastric ulcer and carcinoma caused by bacteria Helicobacter polori. 
Cytotoxin-associated antigen A (CagA) is the key virulent factor of this pathogen. When 
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CagA is introduced to the host cell, it will be phosphorylated, mimic a host scaffolding 
adaptor, e.g. Gab2 and activate Shp2. CagA and Shp2 together contribute to gastric 
epithelial cell transformation [26] 
 
Our research focus of Shp2  
The crystal structure of Shp2 demonstrated one mechanism of Shp2 activity regulation 
through N-SH2 domain. But the C-tail was missing in the structure, therefore the 
structure of the C-tail in the context of the full length Shp2 and its regulatory role in Shp2 
function were not clear. Upon growth factor stimulation, Shp2 associates with receptor 
tyrosine kinases and the C-tail of Shp2 is phosphorylated mainly at two sites, Y542 and 
Y580 [10]. Earlier studies had controversial results about the effect of tyrosine 
phosphorylation on the phosphatase activity of Shp2. In addition, the tyrosine 
phosphorylation of C-tail is always accompanied by the SH2 domain engagement. 
Therefore it was difficult to separate the effect of tyrosine phosphorylation from that of 
the SH2 domain engagement. One group made a great effort to incorporate a 
nonhydrolysable phosphotyrosine mimic at 542 or 580 sites. Their results demonstrated 
the selective intramolecular interaction between C-SH2 and phosphotyrosine mimic at 
580 or between N-SH2 and phosphotyrosine mimic at 542, both of which consequently 
increased the phosphatase activity [27]. Additional  studies from the same group showed 
the additive effect on the stimulation of Shp2 activation by dual interactions between the 
two pairs [28]. The observations with nonhydrolysable chemical mimics of 
phosphotyrosine showed us the possibilities of intramolecular interaction but whether it 
represent the events happening in physiological conditions need to be examined. It is 
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uncertain whether this intramolecular binding actually occurs in cells and if so, whether it 
increases Shp2 activity. In addition to its possible role of regulating Shp2 activity, it is 
not hard to imagine the other possible roles of intramolecular interaction in cells. First, 
intramolecular interaction between SH2 domain and phosphorylated tyrosine can prevent 
the trans/auto-dephosphorylation. Second, intramolecular interaction can limit the access 
of phosphorylated tyrosine by other SH2 domain containing protein. All these questions 
need to be addressed properly. 
 
PDGF Signaling Pathway 
PDGFs and PDGFRs  
We study Shp2 functions in the context of PDGF signaling. Therefore it is essential to 
understand the signaling cascade initiated by PDGF and its cellular and physiological 
importance. PDGF was originally purified from human platelets; hence the name platelet 
derived growth factor. It is a soluble protein circulating in blood. There are four PDGF 
polypeptide chains discovered so far, PDGF-A, B, C and D. PDGF-A and B chains are 
synthesized as precursors which undergo proteolytic cleavage before they are secreted, 
while PDGF-C and D chains are proteolytically cleaved after they are secreted [29, 30]. 
Next PDGFs are activated and dimerized by inter-peptide disulfide bonds. There are 
totally four homodimers of PDGFs, PDGF-AA, BB, CC and DD and one heterodimer, 
PDGF-AB. These 5 isoforms of PDGFs are the active ligands that bind to PDGFRs, 
which belongs to RTKs. Two isoforms of PDGFRs, PDGFRα and PDGFRβ, both contain 
an extracellular domain, a transmembrane domain and an intracellular domain. PDGF-A 
binds to PDGFRα only whereas PDGF-B can bind to both receptors. The extracellular 
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domain of the receptors has three Ig domains while the intracellular domain is further 
divided into a juxtamembrane domain, the kinase domain with an insert and the C-
terminal tail.  
 
Once mature PDGF dimers bind to PDGFRs, they bring two PDGFRs close to each other 
causing receptor dimerization, which is a general strategy for the activation of RTKs. In 
addition to induce receptor dimerization, ligand binding also changes the conformation of 
the kinase domain, causing the activation of kinase and subsequent autophosphorylation 
of tyrosine residues within receptors. There are generally two functions of these receptor 
autophosphorylation: one being regulating kinase activity of the receptor and the other 
being providing binding site for downstream signaling molecules. E.g. phosphorylation 
of Y857 in the PDGFRβ receptor increases the kinase activity of the receptor [31]. 
Phosphorylated tyrosines in PDGFRs can bind to SH2/PTB domain containing 
downstream molecules, passing the PDGF signal across the membrane and propagating it 
into cytosol/nucleus. 
 
Signaling molecules downstream of PDGFRs  
So far there are many identified autophosphorylation sites in the PDGFRs, each with 
distinctive binding partners. The specificity of a certain binding pair is determined by the 
primary amino acids around the phosphotyrosine sites, with the amino acids C-terminal 
of the phosphotyrosine more important for SH2 domain interaction while the amino acids 
N-terminal more important for PTB domain interaction. So far, no binding partner binds 
to the phosphotyrosine sites in PDGFRs though PTB domain interaction therefore we will 
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focus on the downstream signaling molecules that contain SH2 domain. The SH2 domain 
containing downstream signaling molecules can be further categorized into three groups: 
enzymes (e.g. kinases and phosphatases), adapter proteins, which lack catalytic activity 
and some transcription factors. Each downstream molecule initiates its own signaling 
cascades and sometimes these pathways affect each other by cross-talk. I will summarize 
a few well known pathways with more elaboration on Shp2 initiated signaling. 
 
One of the enzymes that bind to PDGFRs is phosphoinositide 3’-kinase (PI3’K), which 
can bind to pY740 and pY571 of PDGFRβ as well as pY731 and pY742 of PDGFRα [32, 
33]. They are lipid kinases which can phosphorylate membrane lipids, phosphoinoditides, 
and are composed of two subunits: p85 regulatory unit and p110 catalytic unit. It is the 
SH2 domain of the regulatory subunit p85 that binds to PDGFRs, which brings catalytic 
subunit close to its membrane substrates. PI3’K catalyses the generation of PIP3 from 
PIP2, which in turn have several downstream effectors, such as, Vav and serine/threonine 
kinase Akt. Vav is a guanine nucleotide exchange factor (GEF) which can further 
regulate RhoGTPase Rac and therefore control cytoskeletal rearrangements and cell 
migrations [34]. Akt is an important regulator of apoptosis. Other enzymes that are able 
to bind to PDGFRs include Src kinase, phospholipase C (PLC), and RasGAP. 
 
One example of the adapter proteins that can directly bind to PDGFRs is Grb2. Grb2 can 
bind to pY716 and pY775 of PDGFRβ through its SH2 domain while its SH3 domains 
bind to Sos, which is a GEF and activate Ras. Downstream Ras is the serine/threonine 
kinase Raf, which can initiate the MAPK pathway. In addition to direct binding to 
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PDGFRs, Grb2 can also form a complex with PDGFRs through other proteins, e.g. Shc 
and Shp2 [35, 36]. Other adapters associated with PDGFRs are Shc, Nck, Crk etc. 
 
Some transcription factors can bind to PDGFRs too. The SH2 domain of Stats (signal 
transducers and activators of transcription) is capable of binding to pY579, pY581 and 
pY775 of PDGFRβ [37]. In addition to SH2 domain, Stats has a DNA binding motif, a N-
terminal region, and a C-terminal transactivation domain. Upon binding to PDGFRs, 
Stats undergo phosphorylation on conserved C-terminal tyrosines, which can promote the 
dimerization of Stats and the subsequent translocation to the nucleus. Several Stats, 
including Stat1, Stat3, Stat5 and Stat6 have been shown to interact with phosphorylated 
PDGFRβ.  
 
Shp2 downstream of PDGFRs  
Shp2 during PDGF signaling is the focus of our study therefore we will describe in 
details the activation mechanisms and downstream effects of Shp2 after PDGF 
stimulation. Shp2 can bind to pY1009 and pY763 of PDGFRβ as well as pY720 and 
pY754 of PDGFRα through SH2 domains [38, 39]. Before binding to PDGFRs, Shp2 has 
an autoinhibition structure with extensive interaction between N-SH2 and PTP domain, 
blocking the catalytic cavity of PTP and reducing the binding affinity of N-SH2. C-SH2 
however is not in direct contact with PTP therefore free to probe its binding partners. 
Afadin has been shown to be a binding partner of C-SH2 during PDGF signaling [40]. 
Even though there is no evidence of direct PDGFR and C-SH2 binding so far, it is still 
possible that C-SH2 binds to PDGFRs first and bring N-SH2 domain closer to PDGFRs.  
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Once N-SH2 binds to PDGFRs, it changes conformation and activates Shp2 by releasing 
the inhibition on PTP domain. Activated Shp2 at membrane dephosphorylates its 
substrate, e.g. pY771 of PDGFR, which is the binding site for RasGAP [41]. So the 
activation of Shp2 can increase Ras/MAPK activity. In addition, Shp2 gets 
phosphorylated on the C-terminal tyrosine sites after PDGF stimulation. The 
phosphorylated tyrosines create binding sites for other SH2 domain containing molecules, 
e.g. Grb2. Both Y542 and Y580 had the consensus sequences for Grb2 binding and there 
have been reports of both sites binding to Grb2, which can also lead to activation of 
Ras/MAPK pathway. 
 
Cellular responses to PDGF  
The primary targets of PDGF are cells of mesenchymal origin, e.g. fibroblasts, smooth 
muscle cells and glial cells. Even with the same PDGF stimulation, different types of 
cells would respond differently obviously due to different cellular context. But even the 
same cell type would have distinct responses to PDGF at various stages or under diverse 
conditions still due to different cellular context, such as different protein expression level. 
As I have just shown above, there are many signaling molecules downstream of PDGFR, 
each leads to distinct but maybe multiple downstream targets, forming a complicated 
network. Crosstalk between pathways, positive and negative feedbacks added to the 
complexity. The same PDGF stimulation input would generate different cellular 
responses/output from the integration of network, which is dependent on cellular context. 
There are several possible outputs of PDGF signaling. First is cell proliferation. 
Ras/MAPK pathway described above is crucial for the PDGF-induced DNA synthesis 
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hours after the initial stimulation by PDGF. Several other pathways, e.g. PLC, are also 
implied to participate for PDGF-induced mitogenic response [42]. Another well studied 
cellular response to PDGF is actin reorganization and cell migration. PI3’K pathway 
activated by PDGF has been shown to activate Rac, which is a small GTPase that can 
cause actin reorganization to form lamellopodia. Actin reorganization is important for 
cell migration, which includes random migration (chemokinesis) and directed migration 
(chemotaxis). Even though PI3’K pathway is the major contributor to PDGF-induced 
actin reorganization and migration, other pathways, e.g. Ras-MAPK, are also playing 
roles in this particular response [43]. Besides these two major cellular responses of PDGF, 
some research has shown that PDGF can also induce cellular differentiation in some 
systems. Cultured PC12 cells can differentiate toward neurons with PDGF stimulation 
[44]. In addition to its mitogenic effect, PDGF can also prevent apoptosis through PI3’K 
and Akt pathway [45]. Therefore, PDGF is a growth factor which can induce different 
cellular responses. 
 
PDGF signaling and diseases 
PDGF signaling has been shown to be important to several physiological processes, e.g. 
development and wound healing. However, it’s the connection between PDGF signaling 
and diseases, especially cancer made PDGFR an important target for drug development. 
Several lines of evidence showed the link between PDGF signaling and cancer. First is 
that PDGF-B is homologous to the transforming v-sis oncogene. Second, PDGF ligands 
and receptors have been shown to be expressed in various tumors, e.g. glioma. Third, 
genetic mutations of PDGFRβ have been detected in some cancer patients. One well 
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studies example is Tel-PDGFRβ. This abnormal fusion protein is a product of a 
translocation between chromosome 5 and 12, causing the transcription factor Tel with the 
kinase domain of PDGFRβ [46]. Tel has dimerization property which causes the 
constitutive activation of PDGFR and cell transformation. Based on the evidence, 
inhibitors for PDGFR have been developed to treat cancers. One successful inhibitor is 
imatinib, which inhibits not only PDGFR but also v-Abl and c-KIT kinases. This 
inhibitor entered clinical trials and was later approved for its effective treatment for 
chronic myelogenous leukemia [47]. 
 
FPs and FRET-based Reporters 
Fluorescent proteins (FPs)   
Martin Chalfie, Osamu Shimomura, and Roger Y. Tsien were awarded the 2008 Nobel 
Prize in Chemistry for their discovery and development of the green fluorescent protein 
(GFP). Since the discovery of GFP in 1960s, FPs have been studied, developed and 
utilized in various kinds of research, revolutionizing the field of live cell imaging. Many 
marine organisms have GFPs but it was first isolated from the jellyfish Aequorea victoria 
and we will only discuss about this specific GFP. Osamu Shimomura was the first to 
isolate GFP from the jelly fish and Martin Chalfie expressed GFP as a marker for gene 
expression in E. coli and C. elegans independent of other cofactors [48]. However, wt 
GFP has some weaknesses not suitable for live cell imaging: mixture chromophore 
population, dimerization tendency, inefficient folding at 37oC, low fluorescence 
brightness and low photostability.  Roger Y. Tsien engineered GFP through mutagenesis 
of wt GFP and improved in all the aspects mentioned above [49]. Most of green FPs 
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being used now is EGFP or Emerald after the engineering. Furthermore, Roger Y. Tsien 
developed multiple colors of FPs derived from wt GFP, e.g. FPs emitting blue (EBFP), 
cyan (ECFP, Cerulean, CyPet, mTFP1 etc) or yellow fluorescence (EYFP, Citrine, Venus, 
YPet, etc). 
 
In addition to GFP and its derivatives, other FPs have been isolated from marine 
organisms, e.g. DsRed from coral Discosoma. The excitation and emission wavelengths 
of DsRed are distinctive from those of GFP. Therefore, DsRed can be combined with 
GFP or its derivatives to label multiple molecules at the same time. DsRed has many 
advantageous properties for live cell imaging, e.g. high fluorescent brightness, resistance 
to photobleaching. But it tends to form tetramers, which leads to the effort to monomerize 
DsRed. Moreover, DsRed has long maturation time and needs improvement. After an 
extensive set of 33 mutations from wt DsRed, monomeric RFP was developed [50]. Later, 
directed evolution and iterative somatic hypermutation methods generated a whole array 
of monomeric FPs named after fruits according to their emission fluorescence, e.g. 
mBanana, mCherry, mOrange, which greatly expanded the available colors of the FP tool 
box [51, 52]. 
 
Many other types of FPs have been discovered and utilized based on their individual 
properties. Some FPs can change their fluorescence intensity (photoactivation) or color 
(photoconversion) upon illumination by lights. For example, a variant of GFP can 
increase green fluorescence 100 times after intense irradiation with UV light [53]. 
Another newly discovered coral protein, Kaede, can be converted to red from green after 
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UV irradiation [54]. More engineered fluorescent proteins with distinct functions, such as 
Killer Red, timer fluorescence proteins, have their unique application and will not be 
discussed in detail here. 
 
FRET-based reporters 
Fluorescent/ Förster resonance energy transfer (FRET) describes the quantum mechanism 
of energy transfer between two fluorophores. Several things determine whether FRET 
can occur between donor and acceptor and how efficient it is. First is that the emission 
spectrum of the FRET donor has to overlap with the excitation spectrum of the acceptor. 
Otherwise the emission from the donor is impossible to excite the acceptor. Second, the 
distance between the donor and acceptor is crucial for FRET efficiency. For efficient 
FRET to occur between donor and acceptor, they have to be close to each other, normally 
less than 10 nm. The distance between donor and acceptor has a dramatic effect on FRET 
efficiency. Therefore, FRET can be used to monitor the distance between the 
fluorophores linked to their targets. In addition, the relative orientation between the donor 
and acceptor affects the FRET efficiency.  
 
Chemical dyes have been used for FRET but since the discovery of FPs, different FPs 
have been paired up to be FRET donors and acceptors. It was only possible with many 
color of different FPs. Early studies used EBFP and EGFP as the FRET pair but the poor 
fluorescence and photostability of EBFP limited its application. ECFP and EYFP is more 
preferred pair because ECFP has better brightness and photostability than EBFP. Variants 
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of ECFP and EYFP have also been paired to test the FRET efficiency between the donors 
and acceptors.  
 
The availability of reliable FRET pairs made it possible to construct genetically encoded 
FRET biosensors, which can be introduced to cells easily as DNA and expressed 
transiently or stably and then be translated to protein in cells. Intermolecular FRET from 
the donor and the acceptor fused with their target molecules have been widely used to 
probe protein-protein interactions and is not the topic here. Instead we are discussing 
intramolecular FRET-based reporters. The basic design of these FRET reporters consists 
of a donor and an acceptor fused in the same molecule together either with a target 
molecule capable of conformational changes or together with two domains capable of 
intramolecular interaction. After stimulation is applied or removed, the target molecule 
undergoes conformational change or the two domains starts to interact, which can alter 
the distance and/ relative orientation of the donor and the acceptor and therefore change 
FRET efficiency. Using this strategy, many single-molecule FRET-based reporters have 
been developed, e.g. Calcium sensor or Cameleon, proteases sensor, cAMP sensor, 
tyrosine/serine/threonine kinase sensor, GTPase sensor. I will discuss in detail one of 
them to elucidate the general working mechanism of the FRET-based reporters.  
 
Src kinase was the first tyrosine kinase discovered and is shown to be an oncogene. It is 
an important signaling relay molecule in different signaling pathways. Therefore it is 
crucial to understand the real time Src kinase activity in live cells upon stimulation. Src 
reporter is designed to have a FRET pair fused with a SH2 domain from Src and a short 
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peptide from a Src substrate. Upon Src activation, Src kinase will phosphorylate the 
peptide substrate and enable its intramolecular interaction with the SH2 domain, which 
will change the conformation of the reporter and alter FRET efficiency in the Src reporter 
case. It has been used to monitor the Src activation in both PDGF and EGF signaling 
pathways. A 25-30% increase of YFP/CFP emission ratio was observed upon growth 
factor stimulation in live cells, indicating a decrease of FRET efficiency upon Src 
activation [55]. It has also been used to detect Src activation upon mechanical stimulation. 
Only with this reporter, spatial and temporal patterns of Src activation can be revealed 
following mechanical stimulus. It was found that a local mechanical stimulus by laser 
tweezer on human umbilical vein endothelial cells can not only initiate a directional wave 
propagation of Src activation along the plasma membrane but also start a rapid distal Src 
activation [56]. In addition, membrane targeted Src reporters revealed differential 
subcellular activation patterns of Src, showing the power of the genetically encoded 
biosensor [57].  
 
FRET-based approach to study Shp2  
Our approach to study the C-tail function of Shp2 is based on FRET. FRET has been 
applied as a tool to detect conformational change of proteins or protein-protein 
interaction. Here we utilize ECFP/YPet FRET pair, which has been shown to have a great 
dynamic range [58]. We will directly fuse Shp2 with the FRET pair to construct the Shp2 
biosensor. The conformational changes observed with the biosensor would likely 
represent the events happening to endogenous Shp2 since we use full length Shp2 in the 
biosensor. So our FRET-based Shp2 biosensor will be a useful tool to imaging Shp2 
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conformational change in live cells. With mutagenesis, we can further dissect the 
mechanism of Shp2 biosensor intramolecular interaction and its functional roles in 
signaling.  
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Chapter 2 
Tunable Intramolecular Interactions between C-SH2 
and C-terminal Phosphotyrosines within Shp2 
Abstract 
We have developed a molecular reporter based on fluorescence resonance energy transfer 
(FRET) to investigate how the tyrosine phosphorylation of the C-terminal tail (C-tail) of Shp2 
regulates its conformational changes and subsequently functions. In vitro incubation of Shp2 
reporter with PDGFRβ induced a significant FRET increase via intramolecular interaction 
between C-SH2 and phosphotyrosine 580 (pY580). The phosphotyrosine 542 (pY542) has an 
adverse position despite a favored surrounding amino acid sequence such that it can only bind to 
C-SH2 in the absence of pY580. In contrast, pY542 dominates the binding of C-SH2 in mouse 
embryonic fibroblasts (MEFs). This intramolecular binding is essential for the subsequent 
effective phosphorylation of Y580, which is then sequestered by Grb2 in cells. These results 
suggested that the cellular environment can tune and switch the interaction of C-SH2 toward 
pY542. When the sequences containing Y542 and Y580 were engineered to exchange their 
positions such that the favored sequence containing Y542 is located at the advantageous position 
of 580 (Y542’), pY542’ constitutively dominates the binding of C-SH2 both in vitro and in 
MEFs. This rewiring of intramolecular interactions within Shp2 also caused a reprogramming of 
downstream signaling events, resulting in a more transient ERK phosphorylation. Therefore, our 
results indicate that the combination of a favorable sequence with an adverse position can create 
a delicate balance and plasticity of intramolecular interactions, which can determine the 
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downstream cellular signaling/functions, and may represent a general design principle for 
functional molecular units tunable by environmental inputs.   
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Introduction  
Src Homology 2 Domain-containing Protein Tyrosine Phosphatase 2 (Shp2), encoded by 
PTPN11, is a protein tyrosine phosphatase (PTP) playing critical roles in various patho-
physiological processes[1]. Mutations of Shp2 have been found in patients of Noonan Syndrome 
[2], LEOPARD syndrome [3], and juvenile myelomonocytic leukemia[4, 5]. Shp2 has also been 
well documented to participate in signaling transduction, particularly in maintaining sustained 
ERK activation in response to growth factor stimulation[6, 7].  
 
Shp2 is structurally similar to another PTP, Shp1, sequentially containing two SH2 domains (N-
SH2 and C-SH2), a PTP domain, and a C-terminal tail (C-tail). However, Shp2 and Shp1 have 
been reported to mainly serve as positive and negative regulator of various signaling 
transductions, respectively [8], with the difference in function attributed to distinct C-tails of 
Shp2 and Shp1[9, 10]. This importance of Shp2 C-tail is further underscored by the observation 
that the removal of the C-tail after residue 538 caused a significant increase in Shp2 phosphatase 
activity[11]. Introducing phosphotyrosine mimetic phosphonomethylene phenylalanine  at either 
tyrosine 542 (Y542) or tyrosine 580 (Y580) of the C-tail of Shp2 also resulted in an activation of 
Shp2[12, 13]. In addition, mutation of either Y542 or Y580 was shown to inhibit the sustained 
ERK activation in response to PDGF and FGF [6]. These results highlight the crucial roles of the 
two tyrosine sites within the C-tail of Shp2. However, the role of phosphorylation at these 
tyrosine residues within the C-tail in regulating the conformational changes and subsequently 
functions of Shp2 remains a mystery. 
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In this study, we inserted the full-length Shp2 between two fluorescent proteins (FPs) forming a 
fluorescence resonance energy transfer (FRET) pair to study the regulatory mechanisms of the 
intramolecular interactions involving the tyrosine sites at the Shp2 C-tail. Our results revealed 
tunable intramolecular interactions between the tyrosine sites of the Shp2 C-tail and their partner 
C-SH2 domain within Shp2, which can be described by a circuit model. Based on the circuit 
model, we rewired the functional units of Shp2 and showed that the rewired intramolecular 
interactions can reprogram the downstream ERK phosphorylation. 
 
Materials and Methods 
Reporter construction and other constructs  
Shp2 reporter was constructed by fusing full length human Shp2 cDNA with an N-terminal 
ECFP sequence and a C-terminal YPet sequence in pRSETb (Invitrogen) for bacterial 
expression. Shp2 reporter was cloned into pcDNA3.1 (Invitrogen) behind a Kozak sequence for 
mammalian cell expression using BamHI/EcoRI restriction sites. Point mutations of Shp2 
reporters were generated using QuikChange Site-Directed Mutagenesis Kit (Stratagene). The 
deletion and insertion mutations of Shp2 reporter were generated by PCR and subsequent 
ligation. MycERK2 and Tel-PDGFRβ constructs were from Drs. Shu Chien [14] and Gary 
Gilliland[15], respectively. 
  
Cell culture and transfection  
Cell culture reagents were obtained from Invitrogen. MEFs and HEK 293 cells (ATCC) were 
maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 unit/ml penicillin, 
100 g/ml streptomycin, and 1 mM sodium pyruvate, and kept in a humidified incubator at 37°C 
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with 5% CO2. DNA plasmids were transfected into MEFs or HEK cells using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s protocol. After transfection, MEFs were 
starved in DMEM containing 0.5% FBS for 36-48 hr before imaging or lysis.  
 
Microscopy, image acquisition and analysis 
Glass-bottom dishes (Cell E&G) were coated with 20 µg/ml fibronectin (Sigma) overnight at 
37°C. Transfected MEFs were then plated on these fibronectin-coated glass-bottom dishes 
overnight in DMEM containing 0.5% FBS before imaging. During imaging, MEFs were 
maintained in CO2-independent medium (Invitrogen) with 0.5% FBS at 37°C before being 
treated with 20 ng/ml PDGF (Sigma). Images were obtained on a Zeiss Axiovert inverted 
microscope equipped with a cooled charge-coupled device camera (Cascade 512B; 
Photometrics) using MetaFluor 6.2 software (Universal Imaging). The following filter sets 
(Chroma) were used in our experiments for FRET imaging: a dichroic mirror (450 nm), an 
excitation filter 420/20 nm, an ECFP emission filter 475/40 nm, and a FRET emission filter 
535/25 nm. The signals from transfected cells were subtracted by background signals from non-
transfected cells. The emission ratio (FRET/ECFP) for the images were then computed and 
generated by MetaFluor software to represent the FRET efficiency. The emission ratio were 
quantified and analyzed by Excel (Microsoft). 
 
Immunoprecipitation and immunoblotting 
Treated or untreated cells were washed three times with ice-cold PBS and lysed in a buffer (Cell 
Signaling) containing 50 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1% Triton X-100, 0.1% SDS, 5 
mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml leupeptin. Lysates 
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were centrifuged at 10,000 x g at 4 °C for 10 min, and the protein concentration of clarified 
lysates was determined by Bradford assay (Biorad). Antibody for IP was incubated with cell 
lysate for 1 hr at 4°C.  Protein A/G beads (Santa Cruz) were then added to the mixture for 
incubation overnight at 4°C. The beads were then washed three times with lysis buffer and 
boiled for 5 min SDS protein loading buffer. Afterwards the beads were centrifuged down, the 
supernatant was loaded onto SDS-polyacrylamide gels and subjected to electrophoresis. The 
proteins were then transferred onto a nitrocellulose membrane and blocked with 5% non-fat milk 
or 5% bovine serum albumin in TTBS buffer (50 mM Tris-HCl, 145 mM NaCl, 0.05% Tween-
20, pH 7.4) for 2 hr at RT. The membrane was further incubated with primary antibodies 
overnight at 4°C. After being washed, the membrane was incubated with HRP-conjugated 
secondary antibodies for 2 hr at RT. The signal was detected using SuperSignal Western Pico or 
Femto ECL Kit (Pierce). Polyclonal anti-phospho-SHP-2 (Tyr-542) and (Tyr-580) antibodies 
were from Cell Signaling Technology. Polyclonal anti-GFP antibodies for IP were from Abcam. 
Monoclonal anti-phosphotyrosine pY20 antibody was from BD Transduction laboratory. 
Monoclonal and Polyclonal anti-Shp2 antibodies, polyclonal anti-GFP antibodies for 
immunoblotting as well as HRP conjugated secondary antibodies were purchased from Santa 
Cruz Biotechnology.  
 
Protein expression and purification 
HEK cells transfected with wild type or mutated Shp2 reporters were first washed with cold PBS 
and then lysed in buffer containing 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.2 
mM PMSF, 0.2% Triton X-100 and protease inhibitor cocktail tablet (Roche). Lysates were 
centrifuged at 10,000 x g at 4°C for 10 min. The reporter protein contains a 6-His tag at its N-
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terminus. Therefore, the supernatant was incubated with Ni-NTA agarose beads (Qiagen) for 
coupling. The coupled agarose beads were washed with washing buffer (50 mM Tris-HCl pH 
7.5, 100 mM NaCl, 10 mM imidazole,) and subsequently RIPA buffer (50 mM Tris-HCl pH 7.5, 
100 mM NaCl, 1 mM EDTA, 0.2% Triton X-100, 1% sodium deoxycholate, 0.1% SDS.) 
Reporter proteins were eluted in a buffer containing 50 mM Tris-HCl pH 7.5, 100 mM NaCl, and 
100 mM imidazole. Alternatively, reporter proteins were purified from E. coli. Reporters in 
pRSETb expression vector system were transformed into BL21 and the expression was induced 
by 0.4 mM IPTG for 16 hr at room temperature. The bacteria were lysed in buffer A (20 mM 
imidazole, 20 mM Tris-HCl pH 8, 200 mM NaCl) with EmulsiFelx-B15 (Avestin). Lysates were 
centrifuged at 10,000 x g at 4°C for 20 min. The supernatant was loaded onto a HisTrap HP 
column with an AKTApurifier FPLC system (GE). The column was washed with 20 ml of buffer 
A and the fusion protein eluted using 20-400 mM imidazole concentration gradient developed in 
50 ml buffer A at 0.5 ml/min. Fractions with absorption at 430 nm were pooled, concentrated 
and subsequently loaded onto a HiLoad 16/60 Superdex 200 gel filtration column (GE). Buffer B 
(30 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM dithiothreitol) was used for elution. Fractions 
around MW 120 kDa were collected and concentrated for in vitro assay. 
 
In vitro kinase assay 
Purified proteins were dialyzed overnight at 4°C in kinase buffer (50 mM Tris-HCl pH 8.0, 100 
mM NaCl, 10 mM MgCl2, and 2 mM dithiothreitol). Fluorescence emission spectra of the 
purified reporters (0.5 µM) were measured in a 96-well plate with an excitation wavelength of 
430 nm using a fluorescence plate reader (TECAN, Sapphire II). For the detection of FRET 
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change of Shp2 reporters, emission ratios of acceptor/donor (526 nm/478 nm) were measured at 
30°C before and after the addition of 1 mM ATP and 20 nM active PDGFRβ kinase (Millipore).  
 
Results 
Previous studies have shown that PDGFRβ kinase can phosphorylate both Y542 and Y580 
within the C-tail of Shp2 in vitro[16]. To assess the effect of this phosphorylation on the 
conformation and function of Shp2, we have engineered a variety of FRET reporters containing 
the full length wild-type (WT) Shp2 or its mutated versions as indicated (Fig. 2.1A and 2.5A). 
Purified WT Shp2 reporter was substantially phosphorylated in vitro by PDGFRβ at both Y542 
and Y580 (Fig. 2.1B), accompanied by an enhancement of FRET efficiency as represented by an 
increase in YPet emission and a concurrent decrease in ECFP emission, indicating a 
conformational change of Shp2 causing FRET acceptor closer to donor (Fig. 2.1C).  To rule out 
the possibility of intermolecular interactions causing FRET increase, PDGFRβ did not cause any 
FRET change of the mixture containing ECFP-Shp2 (Shp2 fused to ECFP alone at its N-
terminus) and Shp2-YPet (Shp2 fused to YPet alone at its C-terminus) (Fig. 2.5A-B), although 
the phosphorylation of both ECFP-Shp2 and Shp2-YPet was significant (data not shown). Hence, 
the reporter FRET response arises from intramolecular interactions within the reporter, but not 
intermolecular contacts between different reporters. In addition, double mutation of both Y542 
and Y580 (YDF) or of the two SH2 domains (RDL) also eliminated the PDGFRβ-induced FRET 
change of the reporter (Fig. 2.1D). Since SH2 domains in the YDF mutant reporter remain intact 
and capable of intermolecular binding to phosphorylated Y1009 of PDGFRβ[17, 18],  the FRET 
response of WT reporter is hence not due to its binding to PDGFRβ in the assay.  Therefore, our 
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observed FRET response of the Shp2 reporter in vitro is mainly attributed to the intramolecular 
interactions between SH2 domains and C-tail tyrosine sites within Shp2.  
 
The R138L mutation in C-SH2 alone blocked the FRET response, whereas R32L in N-SH2 only 
slowed down the initial rate of FRET increase (Fig. 2.1E), possibly by impairing the recruitment 
of reporter toward PDGFRβ[11, 17]. The Y542F mutant of Shp2 reporter did not affect the 
FRET response whereas Y580F blocked almost all FRET increase (Fig. 2.1F). These results 
suggest that the FRET response of WT Shp2 reporter in vitro is mainly due to interaction 
between C-SH2 domain and phosphorylated Y580 (pY580) (Fig. 2.5C). This is consistent with 
the observation that double mutation (R32LY542F) involving both N-SH2 domain and Y542 did 
not eliminate the FRET responses upon PDGFRβ incubation (Fig. 2.5D).  
 
Even though Y580F mutation eliminated most of the FRET enhancement, there was still a minor 
increase of Y580F mutant reporter (Fig. 2.1F inset), suggesting that pY542 may bind to C-SH2 
in the absence of pY580 but only yield a weak FRET change. The 51aa-long flexible C-tail 
region of Shp2 between pY542 (the C-SH2 binding site) and the FRET acceptor YPet may have 
reduced the FRET difference before and after the binding event (Fig. 2.5C). Indeed, the 
truncation of Shp2 C-tail from residue 556 to 593 (Δ580 reporter, Fig. 2.1A), reducing the 
flexible region to 13-aa long, caused a significant increase of FRET change upon PDGFRβ 
incubation in the absence of Y580 (Fig. 2.1G). Furthermore, mutation of R138 (R138LΔ580) but 
not R32 (R32LΔ580) abolished the enhanced FRET response of Δ580 reporter (Fig. 2.5E), 
confirming our hypothesis that pY542 can bind to C-SH2 in the absence of pY580 in vitro. 
Because WT Shp2 reporter showed similar level of FRET response as Y542F reporter, C-SH2 
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selectively and predominantly binds to pY580, but not pY542, in the presence of both 
phosphotyrosines in vitro (Fig. 2.1D and F). 
 
Since pY580 is the primary binding site for C-SH2, it was suspected that the amino acid 
sequence surrounding pY580 is the preferred binding site for C-SH2. Surprisingly, when the 
sequence surrounding Y542 was truncated (residues 538 to 575) so that it was replaced by the 
relocated sequence surrounding Y580 (Δ542 reporter, Fig. 2.1A), no FRET response could be 
observed (Fig. 2.1G), although significant phosphorylation of Y580 occurred upon PDGFRβ 
incubation (data not shown). Considering that the Δ580 reporter has a similar structure as Δ542 
reporter but had a significant increase of FRET upon PDGFRβ incubation via pY542/C-SH2 
binding, the absence of FRET increase indicates that pY580 didn’t bind to C-SH2 in Δ542 
reporter. Therefore, the amino acid sequence surrounding pY542 is likely preferred by C-SH2 
for binding over that surrounding pY580. In addition, when the phosphatase domain was 
truncated from Shp2 and the sequences surrounding Y542 or Y580 were engineered to align at 
the same position, PDGFRβ clearly induced a faster phosphorylation of the Y542 sequence (Fig. 
2.5F). Therefore, the sequence surrounding Y542 is also a better substrate for PDGFRβ than that 
surrounding Y580. Since pY580 is the primary binding site for C-SH2 in WT Shp2 reporter 
where both pY542 and pY580 are intact, the physical position of pY580, which determines the 
C-SH2 binding accessibility, is favored over that of pY542, overpowering the advantageous 
sequence surrounding pY542. Therefore, the combinatorial effect of a favorable position and an 
adverse sequence at pY580 led to the overall preferred binding of C-SH2 toward pY580 over 
pY542 in vitro.  
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Both purified reporter and full-length Shp2 in vitro showed an increased phosphatase activity 
upon incubation with PDGFRβ, which can interact with the N-SH2 domain of Shp2 to release it 
from masking the phosphatase domain and activate Shp2[19] (Fig. 2.5A). When expressed in 
mouse embryonic fibroblasts (MEFs), the reporter can also be recruited to membrane ruffles 
after PDGF stimulation with similar localization patterns and C-tail phosphorylation kinetics as 
the endogenous Shp2 in MEFs (Fig. 2.2C and 2.5B-C). These results confirmed that the 
functions of our Shp2 reporter can mimic that of endogenous Shp2. Hence, we examined the 
intramolecular interactions within Shp2 in live mammalian cells utilizing the reporter, since 
PDGF did not cause intermolecular FRET responses in MEFs expressing both ECFP-Shp2 and 
Shp2-YPet (data not shown).  
 
PDGF caused an obvious FRET increase of the reporter in MEFs (Fig. 2.2A-B), with 
phosphorylation at both Y542 and Y580 (Fig. 2.2C). Consistent with the in vitro results, RDL, 
YDF, or R138L mutation in the reporter, but not R32L, abolished the FRET response in MEFs 
(Fig. 2.2D and 2.7A). Surprisingly, Y542F, but not Y580F, eliminated the PDGF-induced FRET 
response in MEFs (Fig. 2.2D and 2.7A), contrary to the in vitro results. Therefore, C-SH2 and 
pY542 appear to form the primary interaction pair in MEFs, in contrast to C-SH2 and pY580 
pair in vitro. Indeed, Y542 in the Y580F mutant reporter can be sufficiently phosphorylated even 
in the absence of pY580 (Fig. 2.3A) and cause a similar level of FRET change as that of WT 
reporter in MEFs (Fig. 2.2E). Much stronger FRET changes in MEFs upon PDGF stimulation 
were observed with the Δ580 reporter, in which the Y580 sequence was removed to generate a 
shortened linker between pY542 and the FRET acceptor YPet (Fig. 2.5C and 2.7B). This FRET 
response of the Δ580 reporter was abolished by R138L mutation in C-SH2 (R138LΔ580) (Fig. 
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2.7B), confirming that the interaction between C-SH2 and pY542 leads to the FRET response in 
MEFs. 
 
Additional results revealed that the Y580 phosphorylation in Y542F mutant expressed in MEFs 
was significantly inhibited compared to that of WT Shp2 reporter while the phosphorylation 
levels of Y580 and Y542 in vitro were independent of each other (Fig. 2.3A and 2.8A-B). This is 
consistent with a previous report indicating that in fibroblasts Y580 phosphorylation in Shp2 is 
dependent on pY542 [6]. This dependence suggests that the phosphorylation of Y542 may occur 
prior to that of Y580 in MEFs, which is consistent with the in vitro results where Y542-
containing sequence was phosphorylated faster by PDGFRβ (Fig. 2.5F). The disruption of C-
SH2 binding capability by R138L mutation also significantly inhibited the phosphorylation of 
Y580, but not that of Y542 (Fig. 2.3B). These results suggest that the phosphorylation of Y542 
and its subsequent interaction with C-SH2 are essential for sufficient phosphorylation of Y580 in 
MEFs.  
 
Interestingly, when PDGFRβ was over-expressed in MEFs, the Y580 phosphorylation of the 
Y542F reporter was enhanced, causing significant FRET changes upon PDGF stimulation (Fig. 
2.8C-D). This result suggests that sufficient phosphorylation of Y580 can allow its interactions 
with C-SH2 in the absence of pY542 in MEFs similar to in vitro data. It was not clear then why 
the C-SH2/pY580 pair dominates in vitro while the C-SH2/pY542 pair prevails in MEFs to cause 
the FRET responses of WT reporter in which both Y542 and Y580 are sufficiently 
phosphorylated. Since the phosphorylation of Y580 follows and is dependent on C-SH2/pY542 
binding in MEFs, it is possible that binding partners of Shp2 in cell environment can interact 
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with and sequester pY580 to prevent its interaction with pY542-occupied C-SH2. Indeed, 
purified Grb2, but not its SH2 domain mutated version (Grb2RV), reduced the FRET signals 
when added to phosphorylated Y542F reporter in vitro, possibly by interacting with pY580 via 
Grb2 SH2 domain and sequestering pY580 (Fig. 2.3C). Consistent with this data, over-
expression of Grb2, but not Grb2RV, can suppress the FRET level of Y542F reporter in MEFs 
expressing constitutively active Tel-PDGFRβ [15] (Fig. 2.3D). These results indicate that Grb2 
can interact with and sequester pY580 of Shp2 in MEFs, which effectively stabilizes the 
interaction between C-SH2 and pY542.  
 
Taken together, the binding preference of C-SH2 toward either pY542 or pY580 appears to be 
tunable depending on the local environment. We reasoned that this tunability of intramolecular 
interactions might be attributed to subtle preference of C-SH2 in binding to pY580 (with a 
favorable position but an adverse sequence) over pY542. We thus swapped the 11 aa sequences 
surrounding Y542 and Y580 (SWAP reporter) (Fig. 2.1A) to create pY542’, which is 
overwhelming dominant in C-SH2 binding (Y542’: Y542 sequence at 580 position; Y580’: Y580 
sequence at 542 position) by concentrating both preferred position and favorable sequence at the 
580 site. Both Y542’ and Y580’ of the SWAP reporter were phosphorylated independently in 
vitro and in MEFs (Fig. 2.4A-B). In addition, the Y580’ phosphorylation of SWAP reporter was 
significantly lower than the Y580 phosphorylation of WT reporter (Fig. 2.9A). These results 
suggest that the regulatory mechanism for promoting phosphorylation of pY580 by C-
SH2/pY542 interaction in WT reporter is no longer available in the SWAP reporter. PDGF also 
induced a drastic FRET change of the SWAP reporter in MEFs, with a level comparable to the in 
vitro response stimulated by PDGFRβ incubation (Fig. 2.9B-C). The mutation of Y542’, but not 
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Y580’, abolished the FRET response of the SWAP reporter both in vitro and in MEFs (Fig. 
2.4C-D). R138L but not R32L mutation abolished the FRET response of the SWAP reporter 
(Fig. 2.9D-E), confirming that C-SH2 of the SWAP reporter predominantly binds to pY542’ in 
both in vitro and in MEFs. These results indicate that Shp2 utilizes the combinatory effect of 
position and sequence to develop a subtle preference for specific tyrosine site in binding to C-
SH2. This subtle preference allowed a tunable intramolecular interaction within Shp2 under 
different environments. Once the binding preference becomes substantial, the tunability is lost, 
as in the case of the SWAP reporter. The rewired intramolecular interactions within the SWAP 
reporter also had profound impact on the downstream signaling events. Indeed, the ERK 
phosphorylation upon PDGF stimulation in MEFs expressing the SWAP reporter decayed more 
rapidly than those expressing the WT reporter (Fig. 2.4F). However the transient 
phosphorylation of Erk was not altered with SWAP reporter 5min after PDGF stimulation (Fig. 
2.9G). So the rewired Shp2 had targeted effect on sustained Erk phosphorylation. 
 
Discussion 
Molecular functions in live cells are largely dependent on their conformations and intramolecular 
interactions. Our results reveal that Shp2 molecule undergoes different intramolecular 
interactions and adopt varying conformations that are tunable by surrounding molecules in the 
environment: C-SH2 binds to either pY580 (in vitro) or pY542 (in MEFs). This tunable 
molecular conformation of Shp2 is achieved via careful placement of different amino acid 
sequences to create a delicate balance between different intramolecular interactions. The 
sequence surrounding Y542 is a preferred substrate of PDGFR and also a preferred binding 
partner for C-SH2. However, in comparison to Y580, the position of Y542 may sterically hinder 
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binding to C-SH2. This combinatory effect of sequence and position results in a moderately 
favored binding of C-SH2 to Y580 in vitro, where both Y542 and Y580 are sufficiently 
phosphorylated due to excess PDGFR in solution. In MEFs, the recruitment of Shp2 to the 
membrane receptor PDGFR through its N-SH2 domain leads to primary and early 
phosphorylation of the favored substrate Y542 by PDGFR, which subsequently binds to C-SH2. 
This pY542/C-SH2 interaction causes conformational change of Shp2 to facilitate the sufficient 
phosphorylation of Y580, which then recruits Grb2 to sequester the otherwise slightly favored 
pY580 from interacting with the pY542-occupied C-SH2. Based on our results, pY542 
dominates the binding to C-SH2 in MEFs. Therefore, the subtle preference of pY580 for C-SH2 
binding in vitro when both Y580 and Y542 are sufficiently phosphorylated can be reversed by a 
series of well-coordinated molecular regulations in live cells: (1) The preferred phosphorylation 
of Y542 by the limited amount of membrane associated PDGFR precedes and mediates the 
phosphorylation of Y580; (2) The binding of pY580 to Grb2 sequesters pY580 from interacting 
with pY542-occupied C-SH2. In fact, if we swap the positions of Y542 and Y580 sequences to 
disrupt this subtleness by concentrating both favorable sequence and position at 580 site (Y542’), 
C-SH2 constitutively binds to the new pY542’ both in vitro and in MEFs. To conceptualize these 
complex regulation mechanisms, the outcome of C-SH2 binding (or its ensuing FRET response) 
was analogized to be determined by the overall conductance in a signal path of electric circuit 
containing multiple resistors. The size of each resistor in the path represents the relative 
resistance against the phosphorylation or binding event determined by the surrounding sequence 
or position of tyrosine sites. As such, a tunable circuit model can describe the regulation of 
plasticity of intramolecular interactions within Shp2, with a rewired circuit model depicting the 
invariable regulation mechanism for the SWAP reporter (Fig. 2.4F).   
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This intramolecular C-SH2/pY542 interaction in MEFs and the subsequent Shp2 conformational 
change may provide a mechanism to facilitate and ensure the sufficient phosphorylation of Y580, 
an unfavorable substrate for PDGFR. It has been previously reported that an impaired Y580 
phosphorylation as a result of either Y542F or Y580F mutation of Shp2 in fibroblasts can cause a 
less sustained ERK activation[6]. Interestingly, pY580 was constitutively lower in the SWAP 
reporter (Fig. 2.9B), with a concomitant ERK phosphorylation more transient than that of the 
WT reporter (Fig. 2.4F). Therefore, the rewired Y542 and Y580 positions in the SWAP reporter 
may have eliminated the C-SH2/pY542 interaction mechanism that facilitates sufficient 
phosphorylation of Y580, thereby preventing sustained ERK phosphorylation upon PDGF 
stimulation. Indeed, it has been proposed that pY580 may serve as a docking site for Grb2/Sos 
complex and therefore regulate downstream ERK pathway [20]. Since the differential dynamics 
of ERK activation has been shown to  determine the cell fates and important for long-term 
memory [21, 22], the wiring and re-wiring of Y542 and Y580 positions in Shp2 to control pY580 
and hence ERK phosphorylation dynamics can have profound impact on cellular functions.  
 
It becomes increasingly clear that the functions of signaling molecules are largely dependent on 
subcellular locations/compartments. For example, Src induces the p190GAP activation and 
inhibits Rho GTPase at the focal adhesion sites[23], whereas it activates Rho at podosomes [24]. 
This tunable regulatory mechanism built into Shp2 may provide a prominent example on how 
nature can design/evolve molecules with their conformations/functions differentially regulated 
under distinct environment, e.g. at different subcellular locations/compartments. The 
understanding and rewiring of these circuits can provide powerful means to reprogram the 
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downstream signaling cascades, cellular functions, and ultimately physiological 
consequences[25]. This model may also present a general strategy for the design and 
development of basic molecular units tunable by environmental cues. The modification and 
assembly of these units can allow the construction of sophisticated molecular machines that will 
be capable of perceiving the environmental cues, adapt and then alter the cell 
functions/environment accordingly. 
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Tables and Figures 
 
Figure 2.1 FRET studies of intramolecular interactions of the Shp2 reporter in vitro.  A) 
Schematic map and domain structure of the Shp2 reporter and its mutants. The full length human 
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Shp2 is fused between an N-terminal ECFP and a C-terminal YPet. Residues R32 in N-SH2 and 
R138 in C-SH2 are critical sites for phosphotyrosine binding. Y542 and Y580 are the two major 
tyrosine phosphorylation sites at the C-tail. The sequence of 11 amino acid surrounding Y542 
(including 4 residues in front of and 6 residues behind Y542) is marked red while that 
surrounding Y580 is marked green. The Δ542 reporter has a truncation between residue 538 and 
575 to remove the Y542 sequence whereas the Δ580 reporter has a truncation between residue 
556 and 593 to remove the Y580 sequence. SWAP reporters have the 11aa sequences of Y542 
and Y580 exchanged in their positions. Y542’: Y542 sequence at 580 position; Y580’: Y580 
sequence at 542 position. B) The top two panels show the phosphorylation of Y542 and Y580 of 
the Shp2 reporter induced by 20 nM PDGFRβ kinase in vitro at various periods of time. The 
bottom panel shows that the equal amount of Shp2 reporter was loaded on different lanes. C) 
PDGFRβ kinase induced a significant emission spectrum change (simultaneous increase of YPet 
and decrease of ECFP) of the wild-type Shp2 reporter at ECFP excitation (430nm). Black line, 
spectrum before the addition of PDGFRβ; red line, spectrum after the addition of PDGFRβ. D-
G) The time courses of normalized ECFP/YPet emission ratio of WT reporter and its RDL, YDF, 
R32L, R138L, Y542F, Y580F, Δ542 and Δ580 mutants as indicated. In f inset, a zoom-in image 
of the time course of Y580F reporter is shown separately. 
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Figure 2.2 The intramolecular interactions within WT Shp2 reporter in MEFs. A) The time-
lapse ratiometric (FRET/ECFP) images of one representative MEF cell transfected with WT 
reporter before and after PDGF stimulation for various periods of time as indicated. (Scale 
bar=10 µm). B) The time courses of the normalized FRET/ECFP ratio from each individual MEF 
cell expressing WT reporter (grey dots), with the average curve and its standard errors shown in 
black. C) The gel panels show the phosphorylation levels of Y542 and Y580 of the Shp2 reporter 
at different time points in MEFs induced by PDGF stimulation. D) The time courses of the 
normalized FRET/ECFP ratio from each individual MEF cell expressing the indicated mutant 
reporters(grey dots).  The average curve and its standard errors are shown in black. E) The time 
course of the averaged curve and their standard errors of the normalized FRET/ECFP ratio from 
MEFs expressing WT reporter or its mutants as indicated.  
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Figure 2.3 The regulation mechanism of intramolecular interactions in MEFs. A) The top 
panels represent the tyrosine phosphorylation of Y580 and Y542 of the WT reporter, its Y542F 
or Y580F mutant in MEFs before and after 5 min PDGF stimulation. The bottom graphs show 
the quantification of pY542 (left) and pY580 (right) of WT and mutant reporters. *, p < 0.05 
(n=3). B) The top panels represent the tyrosine phosphorylation of Y580 and Y542 of the WT, or 
R138L mutant in MEFs before and after 5 min PDGF stimulation. The bottom graph shows the 
quantification of pY542 and pY580 of WT and R138L reporter. **, p < 0.01 (n=3). C) The time 
courses of normalized FRET/ECFP ratio of the Y542F reporter in vitro upon PDGFRβ 
incubation. The second arrow indicated the addition of Grb2 or its Grb2RV mutant. D) The bar 
graphs represent the averaged FRET/ECFP ratios of the Y542F reporter in MEFs co-expressing 
the constitutively active PDGFR (Tel-PDGFRβ) together with control vector, Grb2, or Grb2RV. 
***, p < 0.001. 
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Figure 2.4 Swapping the Y542 and Y580 sequences disrupted the tunability of Shp2 
intramolecular interactions. A-B) The top two gel panels show the tyrosine phosphorylation of 
Y542’ and Y580’ of the SWAP reporter, its Y542’F, or Y580’F mutant in (A) MEFs before and 
after 5 min PDGF stimulation or (B) in vitro before and after 180 min PDGFR incubation. The 
bottom panels show that equal amount of Shp2 reporters were loaded under different conditions. 
C) The time courses of normalized FRET/ECFP ratio of Y542’FSWAP and Y580’FSWAP 
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mutants in vitro before and after PDGFRβ incubation. D) The time courses of the normalized 
FRET/ECFP ratio from each individual MEF cell expressing either Y542’FSWAP (blue) or 
Y580’FSWAP (purple) reporter before and after PDGF stimulation (dots), with the average curve 
and its standard errors shown in solid lines. E) The left panel shows the phosphorylation of 
immunoprecipitated mycERK2 at different time points of PDGF stimulation in MEFs expressing 
either WT or SWAP reporter. The right panel shows the quantification of pErk leves in MEFs 
expressing either WT or SWAP reporter 20min after PDGF stimulation. *, p < 0.05 (n=3).  F) 
Left: the proposed tunable circuit model depicting the regulation mechanism of intramolecular 
interaction of the WT Shp2 reporter. Right: the rewired untunable circuit model for the SWAP 
Shp2 reporter. Ts: three state gate, OR: OR gate. The size of each resistor represents the relative 
resistance against the phosphorylation (open box) or binding (shaded box) event determined by 
the surrounding sequence (symbol S) or position (symbol P) of tyrosine sites. S542a/S580a, 
resistance against phosphorylation determined by sequence 542 or 580. S542b/S580b, resistence 
against C-SH2 binding determined by sequence 542 or 580. P542/P580, resistance against C-
SH2 binding determined by position 542 or 580. The combined resistance at Y580 path is 
moderately smaller than that of Y542 to cause a preferable pY580 binding to C-SH2 in vitro 
(green). The limitation of transmembrane PDGFR (turning off Ts1 in the pathway) and the 
presence of Grb2 (turning on Ts2 connecting to ground) in MEFs can elevate the threshold in 
activating the pY580 pathway, which effectively promotes the shift of balance toward the 
pathway of pY542/C-SH2 binding in MEFs (red). Under this circumstance, a directional diode 
leading from the pY542/C-SH2 binding pair can also cause the sufficient phosphorylation of 
pY580 as overwhelming PDGFR in vitro does (OR gate). This pY580 in MEFs is then 
sequestered by Grb2 (Ts2 connecting to ground). The SWAP reporter has essentially a rewired 
circuit such that the new Y542’ path has constitutively smaller resistance to allow a dominance 
of this pathway both in vitro and in MEFs (yellow), which eliminates the tunability of the 
intramolecular interactions within Shp2. 
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Figure 2.5  A) Schematic domain structures of different mutant reporters. B) The time courses of 
normalized FRET/ECFP ratio of mixed solution containing both ECFP-Shp2 and Shp2-YPet 
reporters with or without the incubation of PDGFRβ kinase. C) The diagrams depicting the 
conformational changes of the Y542F, Y580F, WT, and Δ580reporters upon phosphorylation. D) 
The time courses of normalized FRET/ECFP ratio of R32LY542F mutant reporter before and 
after the incubation with PDGFRβ kinase. E) The time courses of normalized FRET/ECFP ratio 
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of R32LΔ580 or R138LΔ580 mutant reporter before and after the incubation with PDGFRβ 
kinase. F) The top gel panel shows the overall tyrosine phosphorylation levels of the purified 
ΔPTPY580FSWAP (1 µM) or ΔPTPY542F (1 µM) reporter before and after 10 nM PDGFRβ 
incubation for various periods of time, with the bottom gel panel showing the equal loading 
under different conditions. 
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Figure 2.6 A) The time courses of normalized fluorescence intensity of 6,8-difluoro-4-
methylumbelliferone(product from DiFMUP) to represent the phosphatase activities of purified 
His-tagged full-length Shp2 (left) and WT Shp2 reporter (right) with (“PDGFRβ”) or without 
(“control”) the incubation of PDGFRβ kinase. B) Immunostaining images of endogenous Shp2 
and WT Shp2 reporter in MEFs before and after 5 min PDGF stimulation. White arrows point to 
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membrane ruffles. C) The top two gel panels show the tyrosine phosphorylation of Y542 and 
Y580 of the endogenous Shp2 in MEFs before and after PDGF stimulation. The bottom panel 
shows that equal amount of endogenous Shp2 was loaded under different conditions.  
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Figure 2.7 A) The FRET/ECFP emission ratio images of different mutant reporters as indicated 
before and after PDGF stimulation. B) The time courses of the normalized FRET/ECFP ratio of 
Δ580, R32LΔ580, and R138LΔ580 reporters in MEFs before and after PDGF stimulation (grey 
dots), with the average curve and its standard errors shown in black.  
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Figure 2.8 A) The top gel panel shows the overall tyrosine phosphorylation levels of the 
immunoprecipitated WT reporter, its YDF, Y542F, or Y580F mutant in MEFs before and after 5 
min PDGF stimulation, with the bottom gel panel showing the equal loading under different 
conditions. The graph panel shows the quantification of pY20 of immunoprecipitated WT 
reporters and its mutants. *, p < 0.05 (n=3); *** p < 0.001(n=3). B) The top panels represent the 
tyrosine phosphorylation of Y580 and Y542 as indicated of the WT reporter, its Y542F or Y580F 
mutant in vitro before and after 180 min PDGFRβ incubation. C) The top two gel panels show 
the tyrosine phosphorylation of Y542 and Y580 of the WT or its Y542F mutant reporter before 
and after 5 min PDGF stimulation in MEFs with or without the over-expression of PDGFRβ. The 
bottom panel shows that equal amount of reporter proteins was loaded under different conditions. 
D) The time courses of normalized FRET/ECFP ratio of the Y542F reporter before and after 
PDGF stimulation in MEFs over-expressing PDGFRβ.  
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Figure 2.9 A) The top two gel panels show the tyrosine phosphorylation of Y542 (or Y542’) and 
Y580 (or Y580’) of the WT or SWAP reporter before and after 5 min PDGF stimulation in 
MEFs. The bottom panel shows that equal amount of reporter proteins was loaded under 
different conditions. B) The time courses of normalized FRET/ECFP ratio of SWAP reporter in 
vitro with (“PDGFRβ”) or without (“Control”) PDGFRβ incubation. C) The time courses of the 
normalized FRET/ECFP ratio from each individual MEF cell expressing the SWAP reporter. D) 
The time courses of normalized FRET/ECFP ratio of R32LSWAP and R138LSWAP reporter in 
vitro with PDGFRβ incubation. E) The time course of the normalized FRET/ECFP ration from 
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each individual MEF cell expressing either R32Lswap (purple), or R138Lswap (blue) reporter 
before and after PDGF stimulation (dots), with the average curve and its standard errors shown 
in solid lines.  F) The graphs show the normalized pErk level of MEFs expressing either WT or 
SWAP reporter 5min (left) or 60min (right) after PDGF stimulation. There is no statistical 
difference. 
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Chapter 3 
The Interrelationship between Intramolecular 
Interactions and Phosphatase Activity of Shp2 
 
Introduction 
Shp2 (encoded by PTPN11) is a tyrosine phosphatase containing the Src homology-2 
(SH2) domain and has been shown to play critical roles in various patho-physiological 
processes [1]. In fact, mutations of Shp2 have been found in patients of Noonan 
Syndrome (NS) [2], LEOPARD syndrome (LS) [3], and juvenile myelomonocytic 
leukemia [4, 5]. Recently, Shp2 has also been shown to regulate the long-term memory in 
drosophila by altering the ERK signaling [6].  
 
The activation mechanism of Shp2 is tightly regulated by the N-terminal SH2 domain 
which forms a contact with the PTP domain and hence inhibits the Shp2 activation [7]. 
The disruption of the interface between the N-SH2 and phosphatase domains by an E76A 
mutation of Shp2 drastically elevated the Shp2 phosphatase activity which is sufficient to 
induce Xenopus cap elongation [8]. The binding of N-SH2 domain by activated growth 
factor receptors can cause a relatively large conformational change and release the 
contact to allow the activation of PTP domain [7]. Indeed, EGF receptor  pY992  and 
PDGFR 1009 have been shown to be the most compatible binding peptides for N-SH2 
domain of Shp2 [9]. The phosphorylated Tyr 1009 of PDGFR can specifically bind to the 
N-SH2 domain which recruits and activates Shp2 to dephosphorylate tyrosine 751 and 
771 on PDGFR to inhibit the receptor binding of p85 and Ras GAP, respectively [10]. 
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Consistently, the Tyr 1009 mutation on PDGFR allowed the sustained phosphorylation of 
PDGFR upon PDGF comparing to wild-type PDGFR [10]. At the same time, this 1009 
mutation blocked the Shp2 binding and activation, and subsequently inhibited cell 
migration and FAK-associated activity toward its autophosphorylation [11]. These 
previous studies established the important role of N-SH2 in regulation of Shp2 
Phosphatase activity.  
 
Phosphatase activity is crucial for Shp2 functions in both normal and disease signaling. In 
fact, most mutations of Shp2 found in patients were related to its activity [1]. A lot of 
studies used inactive mutants of Shp2, e.g. C459S to probe the PTP function of Shp2 in 
different signaling pathways. Therefore, it is important for us to study PTP domain of 
Shp2 too. Here we used inhibitors and different inactive mutations of PTP domain to 
probe the significance of PTP domain in regulating intramolecular interactions. 
 
Shp2 contains three domains that can bind to phosphotyrosines, N-SH2, C-SH2 and PTP 
domain. SH2 domains simply bind to phosphotyrosines while PTP domain can bind them 
first then carry out dephosphorylation reaction. So theoretically, pY542 and pY580 are 
possible binding partners and substrates for Shp2’s PTP domain. Therefore, PTP domain 
may play an important role in the phosphorylation and subsequent intramolecular 
bindings of Shp2. It has been considered a paradox that a phosphatase gets 
phosphorylated and presumably the phosphatase can autodephosphorylate itself. 
However, there are limited studies on autodephosphorylation of Shp2 [12]. With our 
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FRET reporter, we may be able to show real time autodephosphorylation through the 
change of FRET level. 
 
We have successfully shown the binding between C-SH2 and pY542/pY580 in Chapter 
2, but whether N-SH2 binds intramolecular phosphotyrosine is not clear. The fact that our 
R138L reporter didn’t display any FRET increase doesn’t mean there were no 
intramolecular interactions between N-SH2 and C-tail phosphotyrosines as no FRET 
change doesn’t mean there is no conformational change. Previous studies using Pmp 
indicated that N-SH2 selectively binds to Pmp542 ([13, 14]). However, our R32LΔ580 
reporter showed that pY542 can bind to C-SH2 in the absence of pY580. In this chapter, 
we will figure out whether N-SH2 can bind to phosphotyrosines and if so, which one it 
prefers, using both FRET and phosphatase assays. 
 
Materials and Methods 
Reporter construction and other constructs 
Shp2 reporter was constructed by fusing full length human Shp2 cDNA with an N-
terminal ECFP sequence and a C-terminal YPet sequence in pRSETb (Invitrogen) for 
bacterial expression. Shp2 reporter was cloned into pcDNA3.1 (Invitrogen) behind a 
Kozak sequence for mammalian cell expression using BamHI/EcoRI restriction sites. 
Point mutations of Shp2 reporters were generated using QuikChange Site-Directed 
Mutagenesis Kit (Stratagene). The deletion and insertion mutations of Shp2 reporter were 
generated by PCR and subsequent ligation.  
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Cell culture and transfection 
Cell culture reagents were obtained from Invitrogen. MEFs were maintained in DMEM 
supplemented with 10% FBS, 2 mM L-glutamine, 100 unit/ml penicillin, 100 g/ml 
streptomycin, and 1 mM sodium pyruvate, and kept in a humidified incubator at 37°C 
with 5% CO2. DNA plasmids were transfected into MEFs using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol. After transfection, MEFs were 
starved in DMEM containing 0.5% FBS for 36-48 hr before imaging or lysis.  
 
Microscopy, image acquisition and analysis 
Glass-bottom dishes (Cell E&G) were coated with 20 µg/ml fibronectin (Sigma) 
overnight at 37°C. Transfected MEFs were then plated on these fibronectin-coated glass-
bottom dishes overnight in DMEM containing 0.5% FBS before imaging. During 
imaging, MEFs were maintained in CO2-independent medium (Invitrogen) with 0.5% 
FBS at 37°C before being treated with 20 ng/ml PDGF (Sigma). Images were obtained on 
a Zeiss Axiovert inverted microscope equipped with a cooled charge-coupled device 
camera (Cascade 512B; Photometrics) using MetaFluor 6.2 software (Universal Imaging). 
The following filter sets (Chroma) were used in our experiments for FRET imaging: a 
dichroic mirror (450 nm), an excitation filter 420/20 nm, an ECFP emission filter 475/40 
nm, and a FRET emission filter 535/25 nm. The signals from transfected cells were 
subtracted by background signals from non-transfected cells. The emission ratio 
(FRET/ECFP) for the images were then computed and generated by MetaFluor software 
to represent the FRET efficiency. The emission ratio were quantified and analysed by 
Excel (Microsoft). 
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Immunoblotting 
The kinase reaction mixture was boiled for 5 min in SDS protein loading buffer and then 
loaded onto SDS-polyacrylamide gels and subjected to electrophoresis. The proteins were 
then transferred onto a nitrocellulose membrane and blocked with 5% non-fat milk or 5% 
bovine serum albumin in TTBS buffer (50 mM Tris-HCl, 145 mM NaCl, 0.05% Tween-
20, pH 7.4) for 2 hr at RT. The membrane was further incubated with primary antibodies 
overnight at 4°C. After being washed, the membrane was incubated with HRP-
conjugated secondary antibodies for 2 hr at RT. The signal was detected using 
SuperSignal Western Pico or Femto ECL Kit (Pierce). Polyclonal anti-phospho-SHP-2 
(Tyr-542) and (Tyr-580) antibodies were from Cell Signaling Technology. Polyclonal 
anti-GFP antibodies for IP were from Abcam. Monoclonal anti-phosphotyrosine pY20 
antibody was from BD Transduction laboratory. Monoclonal and Polyclonal anti-Shp2 
antibodies, polyclonal anti-GFP antibodies for immunoblotting as well as HRP 
conjugated secondary antibodies were purchased from Santa Cruz Biotechnology.  
 
Protein expression and purification 
Reporter proteins were purified from E. coli. Reporters in pRSETb expression vector 
system were transformed into BL21 and the expression was induced by 0.4 mM IPTG for 
16 hr at room temperature. The bacteria were lysed in buffer A (20 mM imidazole, 20 
mM Tris-HCl pH 8, 200 mM NaCl) with EmulsiFelx-B15 (Avestin). Lysates were 
centrifuged at 10,000 x g at 4°C for 20 min. The supernatant was loaded onto a HisTrap 
HP column with an AKTApurifier FPLC system (GE). The column was washed with 20 
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ml of buffer A and the fusion protein eluted using 20-400 mM imidazole concentration 
gradient developed in 50 ml buffer A at 0.5 ml/min. Fractions with absorption at 430 nm 
were pooled, concentrated and subsequently loaded onto a HiLoad 16/60 Superdex 200 
gel filtration column (GE). Buffer B (30 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM 
dithiothreitol) was used for elution. Fractions around MW 120 kDa were collected and 
concentrated for in vitro assay. 
 
In vitro kinase assay 
Purified proteins were diluted in kinase buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 
10 mM MgCl2, and 2 mM dithiothreitol). Fluorescence emission spectra of the purified 
reporters (0.5 µM) were measured in a 96-well plate with an excitation wavelength of 
430 nm using a fluorescence plate reader (TECAN, Sapphire II). For the detection of 
FRET change of Shp2 reporters, emission ratios of acceptor/donor (526 nm/478 nm) 
were measured at 30°C before and after the addition of 1 mM ATP and 20 nM active 
PDGFRβ kinase (Millipore). After 180 min incubation with kinase, 10mM EDTA pH 8 
was added to the mixture and fluorescence emission spectra of the reporter were 
measured at different time points afterwards. 
 
Phosphatase activity assay 
Phosphatase activity was measured using fluorogenic 6,8-difluoro-4-methylumbelliferyl 
phosphate (DiFMUP; Invitrogen) as the substrate. Each kinase reaction contained 50 mM 
Tris pH 8, 100 mM NaCl, 10 mM MgCl2, 2 mM dithiothreitol, 1 mM ATP, 100 nM Src 
kinase and 50 nM Shp2 reporter in a total reaction volume of 100 µl in a well of 96-well 
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plates were done first. Reaction was initiated by the addition of 0.5mM DiFMUP at 30oC. 
Reaction product 6,8-difluoro-4-methylumbelliferone fluorescence signal was measured 
at an excitation of 355 nm and an emission of 460 nm with a plate reader (TECAN, 
Sapphire II). 
 
Results 
N-SH2 domain controls the rate of FRET change in vitro. Our Western blot results 
showed that in vitro the phosphorylation of both Y542 and Y580 by PDGFRβ were 
slower in R32L reporter than in WT reporter (Fig. 3.1 A and B). Even though R32L 
mutation of Shp2 biosensor didn’t abolish the FRET change, it did severely impair the 
speed of FRET change with the same PDGFRβ concentration (Fig. 3.1C). N-SH2 domain 
has been shown to bind to phosphorylated Y1009 of PDGFRβ with high affinity [15, 16]. 
We suspected that R32 mutation would disrupt this binding therefore delay the 
recruitment of PDGFRΒ kinase to phosphorylate Shp2 biosensor, which in turn slows 
down the FRET change of the reporter.  
 
PDGFR kinase activates Shp2 through N-SH2 binding. When PDGFR kinases were 
added to WT Shp2 reporter, there was obvious FRET increase (Fig. 3.1C). Part of the 
mixture was used to assay the Phosphatase activity of Shp2 with fluorogenic substrate 
DiFMUP. WT reporter also displayed an increase of Phosphatase activity when incubated 
with PDGFR kinases depending on the concentrations of the kinase (Fig. 3.1D). It was 
first thought as a direct result of phosphorylation and subsequent intramolecular binding 
event. However, PDGFR kinase didn’t induce any increase of Phosphatase activity of 
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R32L reporter even though it did induce an enhancement of FRET efficiency (Fig. 3.1C). 
It suggested that there was no direct correlation between PDGFR-induced FRET increase 
and Phosphatase activity increase. In addition, the fact that N-SH2 domain was necessary 
for PDGFR-induced Phosphatase activity increase was consistent with auto-inhibition 
model of Shp2’s crystal structure [7]. pY1009 of PDGFR has been shown to bind to both 
N-SH2 and C-SH2 [16]. Therefore, PDGFR kinase may not be a good kinase to use if we 
want to probe the sole effect of intramolecular interaction on phosphatase activity as it 
also binds to N-SH2 and directly activates Shp2. So next we seek to find a kinase that can 
phosphorylate Shp2 reporter in vitro but not bind to SH2 domains directly.   
 
Src kinase can phosphorylate Shp2 reporter in vitro. Next we tried to use Src kinase to 
phosphorylate Shp2 reporters in vitro. Src kinase hasn’t been shown to interaction with 
SH2 domains of Shp2 or to phosphorylate Shp2 in literature but its strong kinase activity 
may have an effect of Shp2 in vitro. Western results showed that Src kinase indeed can 
phosphorylate both Y542 and Y580 in WT reporter (Fig. 3.2A). Src kinase also induced a 
strong FRET increase of WT reporter (Fig. 3.2B and C). In addition, R32L mutation 
didn’t affect Src-induced FRET change (Fig. 3.2C). It suggested that Src kinase, unlike 
PDGFR kinase, can’t directly interact with the SH2 domains of Shp2 reporter and change 
phosphatase activity. Therefore, it is a good substitute kinase to probe the effect of 
phosphorylation-dependent intramolecular interaction without directing interacting with 
SH2 domains itself.  
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So we switched to Src kinase when we wanted to probe the sole effect of intramolecular 
interactions on phosphatase activity. However, the way we did Phosphatase assay after 
kinase assay was not suitable to probe the effect of phosphorylation-dependent 
intramolecular interactions. We had done kinase assay in 100µl mixture and then used 
4µl mixture as the enzyme in phosphatase assay in a total volume of 100µl. The dilution 
effect of kinase reaction mixture from 4µl to 100µl would decrease the phosphorylation 
level of our reporter at both pY542 and pY580 (Fig. 3.6A). In order to maintain the 
phosphorylation of Shp2 reporters during phosphatase assay, we did not take 4ul mixture 
from kinase assay to use in 100µl phosphatase reaction as it is a form of dilution which 
will also change the equilibrium between kinase and phosphatase and therefore shift the 
phosphorylation level. To accurately assay the effect of phosphorylation and subsequent 
intramolecular interactions on phosphatase activity, we directly used the total volume of 
kinase mixture for Phosphatase assay. From Michaelis–Menten equation, we know that 
when substrate concentration is much higher than enzyme concentration, the initial 
velocity of reaction is close to Vmax. So we will use 1000 times more substrate than 
enzyme and use that velocity as an approximation for Vmax. 
 
FRET study alone cannot reveal whether N-SH2 binds to intramolecular 
phosphotyrosines. The phosphotyrosine mimic study suggested that N-SH2 domain and 
phosphorylated Y542 bind to each other [13, 14]. However, the presence of intact N-SH2 
and phosphorylated Y542 in R138A or Y580F mutants couldn’t induce any FRET change 
(Fig. 2.1). There are two possible explanations: first, N-SH2 domain and phosphorylated 
Y542 couldn’t interact with each other so there was no conformational change hence no 
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FRET change; second, N-SH2 domain and phosphorylated Y542 can bind to each other 
and induce conformational change, however, FRET efficiency between two 
conformations and during conformations change were similar and we couldn’t observe 
FRET change. In short, if FRET change is observed, conformational change must have 
occurred. But if no FRET change is observed, it doesn’t mean there is no conformational 
change. To distinguish these two possibilities, we would perform phosphatase assay. 
 
Phosphorylation of WT reporters by Src kinase can induce phosphatase activity 
increase. We incubated 100nM Src kinase with 50nM reporters and then after 1h for 
phosphorylation to reach equilibrium we added 50µM DiFMUP and measure the 
fluorogenic product. From the time course, we can measure the initial velocity, which is a 
close approximation of Vmax as our substrate (DiFMUP) is 1000 times excess of our 
enzyme (reporters). We then normalized the phosphatase activity to 50nM reporters 
without Src kinase. For each reporter, the phosphatase activity was triplicated and the 
increase of phosphatase activity in percentage was calculated. For WT reporter, there was 
a 67.7% increase of phosphorylation induced phosphatase activity (Fig. 3.3A and Table 
3.1). However, if we incubated sufficient Src kinase with YDF reporter in which both 
Y542 and Y580 were mutated, there was only 19.8% increase of phosphatase activity 
(Fig. 3.3B and Table 3.1), suggesting that the tyrosine sites at C-terminal tail was 
necessary for the higher level of phosphatase activity increase in WT. Y542F had a 57.9% 
increase of phosphatase activity after incubation with Src (Fig. 3.3C and Table 3.1), 
larger than the minimal increase YDF reporter displayed and similar to WT reporter, 
suggesting that these two reporters have similar intramolecular binding mechanisms. 
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Surprisingly, Y580F reporter had a tremendous increase (178.7%) of phosphatase activity 
(Fig. 3.3D and Table 3.1), much larger than WT and Y542F reporters. In addition to the 
tyrosine sites, we also investigate the roles of SH2 domains in phosphatase activation. 
R32L reporter showed minimal increase of activity as YDF did while R138L showed 97% 
increase of phosphatase activity with Src kinase incubation (Fig. 3.3E, F and Table 3.1). 
These results indicated that N-SH2 has more impact on phosphatase activity than C-SH2 
domain. 
 
Src kinase induced different levels of phosphatase increase of reporters with distinct 
double mutations. Reporters with single mutations may have a mixture of different 
intramolecular interactions and therefore it was complicated to deduce the effect of each 
intramolecular pairing. To reveal the exact effect of a particular intramolecular pair, we 
generated four reporters with double mutations. R138LY542F displayed 142% increase 
of phosphatase activity (Fig. 3.4A and Table 3.1), while R138LY580F only showed 68.8% 
increase (Fig. 3.4B and Table 3.1). Truncation mutation R138LΔ580 showed similar 
amount of increase as R138LY580F (Fig. 3.6C), confirming the reproducibility of our 
results. Even though R32LY542F showed normal FRET increase by Src (Fig. 3.6D), 
there was very small increase (8.6%) of phosphatase activity with Src kinase incubation 
(Fig. 3.4C and Table 3.1), which is even smaller than YDF reporter. However, 
R32LY580F reporter displayed higher increase (43.2%) of phosphatase activity (Fig. 
3.4D and Table 3.1). 
 
71 
 
Phosphatase inhibitors don’t affect FRET increase of WT reporter. We want to 
investigate the role of PTP domain in regulating phosphorylation and subsequent 
intramolecular interactions of Shp2. First we want to see whether phosphatase activity is 
required for FRET increase. We added NSC-87877, a specific Shp2 Phosphatase 
inhibitor [17], to kinase assay. There was still normal FRET increase compared to WT 
(Fig. 3.5A).  
 
Phosphatase inactive mutants have differential effect on FRET change. We also used 
different phosphatase inactive mutants to probe the effect of phosphatase on 
intramolecular interactions. C459S mutation is at the active site of the Shp2 phosphatase, 
which is essential for the chemical reaction of dephosphorylation. Surprisingly, all FRET 
change was diminished by this single mutation, even though the phosphorylation of Y542 
and Y580 were present (Fig. 3.5B and 3.7A). C459S mutation have been shown to have 
the substrate trapping effect [18], so we tried a nonsubstrate-trapping mutant R465E [19]. 
Residue R465 is very important for substrate binding to the catalytic site therefore the 
mutation cannot bind substrate well enough for dephosphorylation to happen. R465E 
mutant reporter showed obvious FRET increase upon PDGFRβ incubation (Fig. 3.5C) 
compared to control, suggesting that phosphatase activity is not necessary for FRET 
increase we observed with WT Shp2 reporter. Src incubation with R465E reporter 
induced similar level of FRET increase as WT reporter (Fig. 3.5D), confirming the 
hypothesis above. In addition, R465E reporters expressed in MEFs also showed FRET 
increase upon PDGF stimulation (Fig. 3.5E). 
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Discussion 
The role of N-SH2 domain in PDGFRβ-induced phosphorylation and subsequent FRET 
increase of reporters are consistent with previous reports: intermolecular binding between 
N-SH2 and PDGFRβ can activate phosphatase. When we investigate the sole effect of 
intramolecular binding on phosphatase, this intermolecular binding induced phosphatase 
increase can interfere. Therefore, we chose another kinase Src, which doesn’t bind to 
SH2 domains of Shp2, to phosphorylate reporters in vitro without causing direct 
activation. The minimal Phosphatase activity increase of YDF reporter may due to 
phosphorylation of Y62 by Src kinase. Previous studies have shown that Y62D mutation 
also can activate Shp2 [20]. It is possible that Src kinase can also phosphorylate Y62 and 
therefore increase Phosphatase activity. To test this possibility, we will use pY62 specific 
antibody to do Western blot first to see whether Y62 can be phosphorylated by Src. We 
will also generate Y62FYDF triple mutation. If this triple mutation had no Src induced 
phosphatase activity increase, it matches our hypothesis. Then all the future experiments 
will have the additional Y62F mutation in the reporters to eliminate the phosphatase 
activity increase from Y62 phosphorylation. 
 
Even though FRET study alone cannot determine whether N-SH2 binds to intramolecular 
phosphotyrosine, we can deduct from phosphatase assays that N-SH2 can bind to pY542 
or pY580 when C-SH2 is mutated. R138LY580F showed some phosphatase increase 
indicating that N-SH2 could bind to pY542 when both C-SH2 and Y580 were mutated.  
R138LY542F showed high level of phosphatase increase suggesting that N-SH2 could 
bind to pY580 when both C-SH2 and Y542 were mutated. Even though we observed 
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much higher phosphatase activity increase with R138LY542F reporter than with 
R138LY580F, it doesn’t mean that N-SH2 binding to pY580 activates phosphatase better 
than N-SH2 binding to pY542. It is because that Y542 phosphorylation by Src kinase in 
reporters is dependent on Y580. In Y580F mutant reporters, pY542 level is much lower 
than in WT reporters. (Fig. 3.2A and 3.6B). So it is not possible to directly compare 
R138LY542F and R138LY580F phosphatase activity because the phosphorylation levels 
of the respective tyrosine in these two reporters are different.  
 
As we have shown in Chapter 2, intramolecular binding between C-SH2 and pY580 
dominates in vitro. Double mutation of R32LY542F showed no increase of Phosphatase 
activity even though it has normal FRET increase (Fig. 3.4C and 3.6D ). It suggested that 
this intramolecular binding between C-SH2 and pY580 doesn’t change phosphatase 
activity, which is not consistent with previous Pmp study showing the binding between 
C-SH2 and Pmp580 increases phosphatase activity [13]. There were several possible 
reasons for the discrepancy. First, the assay substrates are quite different. In their paper, 
they used two different kinds of substrates (Para-Nitrophenyl Phosphate and Phospho-
RCM-Lysozyme), which had some difference in themselves. We use a third kind of 
substrate DiFMUP because the product of Para-Nitrophenyl Phosphate has an absorbance 
spectrum overlapping with that of ECFP. Second, the assay conditions are different. 
Their assay conditions were optimized for phosphatase but our assay conditions are for 
kinase assay to ensure sufficient phosphorylation. Third, their Pmp proteins may have 
altered behavior compared to our naturally phosphorylated proteins. 
 
74 
 
In our study of Shp2 structure and function, we mainly utilized two assays: FRET assay 
and phosphatase activity assay. From the results of these two assays, we observed no 
direct correlation between FRET increase and phosphatase increase. For example, C-SH2 
binding to pY580 can cause FRET increase but not phosphatase increase. N-SH2 binding 
to either phosphotyrosine can cause phosphatase increase but not FRET increase. C-SH2 
binding to pY542 can cause minimal FRET increase and some phosphatase increase. It is 
due to the structure of Shp2 and the design of our reporter.  
 
So far, we have showed that intramolecular interaction involving N-SH2 can increase 
phosphatase activity while interactions between C-SH2 and pY580 cannot increase 
phosphatase activity. We wonder whether C-SH2 has an effect on phosphatase activity. 
However, R32LY580F showed 43.2% increase of phosphatase activity, suggesting that 
intramolecular binding between C-SH2 and pY542 can increases phosphatase activity. It 
seems that C-SH2 can have differential effect on phosphatase activity depending on its 
intramolecular binding partner. This is possible from the structure point of view because 
pY542 and pY580 are at different positions relative to phosphatase domain. Different 
positions of phosphotyrosines can cause different degrees of conformational change of 
phosphatase domain when they bind to C-SH2 therefore have different effects on 
phosphatase activity. In the context of PDGF signaling in MEFs, the interaction between 
C-SH2 and pY542 may cause additional increase of phosphatase activity by further 
exposing the active site of phosphatase after N-SH2 engagement by PDGFR has already 
relieved some auto-inhibition on phosphatase.   
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We have been investigating the effect of intramolecular interactions on phosphatase 
activity, while in reality phosphatase activity can also effect the phosphorylation of Y542 
and Y580 and subsequent intramolecular interactions. Shp2 has been implicated in 
autodephosphorylation in vitro when kinase was eliminated [12]. When we added 10mM 
EDTA to eliminate kinase in our FRET assay, there was an immediate drop of FRET 
(Fig. 3.7B). Western blot showed that phosphorylation of both Y542 and Y580 were 
decreased after EDTA addition confirming the previous observations (Fig. 3.7C). 
Therefore Shp2 could influence the phosphorylation level through dephosphorylation. 
However, neither specific nor general phosphatase inhibitors change FRET response of 
WT reporters. We expected that with phosphatase inhibited, the phosphorylation of Y542 
and Y580 should be increased therefore FRET change would be increased. Nevertheless, 
there was a reduction when we examined the phosphorylation level with phosphatase 
inhibitors (Fig. 3.7D). Therefore it is likely that NSC-87877 can also inhibit PDGFR 
kinase, which is theoretically possible since the inhibition mechanism of NSC-87877 is 
through binding to the catalytic active site of phosphatase. Since kinases and 
phosphatases carry out opposite functions, they may have active sites with similar 
structures. Because we used much less PDGFR (20 nM) than Shp2 reporter (0.5 µM) in 
our reaction, NSC-87877 may have significant effect on PDGFR even though it should 
have quite different IC50 for PDGFR and Shp2.  
 
It was first uncertain why C459S mutation abolished all the FRET increase with intact 
phosphorylation. Chemical studies have shown that cysteine at the active site of PTP 
domain is the critical amino acid to carry out the dephosphorylation function [21]. Once 
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it is mutated to serine, the chemical reaction can no longer occur therefore the substrate 
would be trapped at the mutated active site [22]. Since pY580 binding to C-SH2 is 
necessary for FRET increase, it is possible that pY580 got trapped by C459S mutation 
and was not available to bind to C-SH2. These results also indicated that in terms of 
affinity to bind to pY580, C459S PTP is better than C-SH2. However, C-SH2 should 
have a higher affinity than WT PTP domain because in WT reporters, C-SH2 is able to 
bind to pY580 in the presence of WT PTP domain. The trapping of pY580 also suggested 
that under WT conditions, pY580 is a substrate for PTP domain and the phosphorylation 
level of Y580 as well as Y542 is under the regulation of its own phosphatase. R465E has 
been used as an inactive but nonsubstrate-trapping mutant of Shp2. R465E reporters 
showed kinase induced FRET increase in vitro as well as PDGF induced FRET increase 
in MEFs, which suggests that phosphatase activity is not directly linked to FRET increase 
we observed but serves to regulate the phosphorylation level and subsequent 
intramolecular interactions. 
 
When PDGFRβ kinase activity was killed by excess EDTA, the FRET level as well as 
Y542 and Y580 phosphorylation level of Shp2 biosensor quickly decreased due to 
autodephosphorylation (Fig. 3.7A and B). The phosphorylation level of Y542 didn’t 
decrease as quickly as that of Y580 after EDTA addition, it suggest that pY580 is more 
susceptible to autodephosphorylation, which is consistent with previous studies [14]. C-
SH2 has been shown to bind pY580, which can prevent/delay auto-dephosphorylation. 
We can further breakdown whether this susceptibility of pY580 is due to sequence or 
position effect. We can first generate new reporters containing ECFP, C459S mutated 
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PTP domain, C-tail and Ypet. We expect to see FRET change once Y542 and/or Y580 is 
phosphorylated by Src kinase and subsequently trapped by C459S PTP domain. We will 
use Y542F and Y580F mutations to check which one is more susceptible to 
autodephosphorylation. Then we can swap Y542 and Y580 and further figure out the 
preference by C459S PTP domain to sequence 542/580 and position 542/580. This would 
a nice parallel study to the preference of pY580 by C-SH2 in vitro due to the combination 
effect of sequence and position. 
 
In summary, we discovered the interrelationship between intramolecular interactions and 
phosphatase activity within Shp2. Intramolecular interactions between N-SH2 and 
pY542/pY580 can increase phosphatase activity while intramolecular binding between C-
SH2 and pY580 has no obvious effect on phosphatase activity. However, C-SH2 and 
pY542 interaction can increase phosphatase activity. In turn, phosphatase activity of 
reporters can autodephosphorylate its own phosphotyrosine and therefore regulate the 
phosphorylation-dependent intramolecular interactions. This may serve as a negative 
regulation mechanism to terminate signaling events. 
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Tables and Figures
 
 
Figure 3.1 The functions of N-SH2 domain. A) The phosphorylation of WT reporter in 
vitro with PDGFRβ incubation. B) The phosphorylation of R32L reporter in vitro with 
PDGFRβ incubation. C) The FRET response of WT and R32L reporter in vitro with 
PDGFRβ incubation. D) The phosphatase activity of WT reporter incubated with 
different PDGFRβ concentrations. E) The phosphatase activity of R32L reporter 
incubated with different PDGFRβ concentrations. 
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Figure 3.2 Src kinase can phosphorylate Shp2 reporters in vitro. A) The 
phosphorylation of WT reporter in vitro with Src incubation. B) The emission spectrums 
of WT reporter before and after Src incubation. C) The FRET response of WT and R32L 
reporters with Src incubation in vitro. 
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Figure 3.3 Src-induced phosphatase activity increase of reporters in vitro. A) Src 
kinase incubation induced phosphatase increase of WT reporter. B) YDF reporter had 
significant yet minimal increase of phosphatase activity. C) Y542F reporter had similar 
level of phosphatase increase as WT. D) Y580F reporter had tremendous increase of 
phosphatase activity after incubation with Src. E) R32L reporter had minimal increase of 
phosphatase activity. F) R138L reporter had increase of phosphatase activity. *, p < 0.05. 
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Figure 3.4 Src-induced phosphatase activity increase of reporters with double 
mutations in vitro. A) Src kinase incubation induced phosphatase increase of 
R138LY542F reporter. B) R138LY580F reporter had significant increase of phosphatase 
activity with Src incubation. C) R32LY542F reporter had minimal increase of 
phosphatase increase. D) R32LY580F reporter had obvious increase of phosphatase 
activity after incubation with Src. *, p < 0.05. 
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Figure 3.5 The functions of phosphatase domain. A) The FRET response of WT 
reporter with or without Shp2 specific phosphatase inhibitor NSC-87877 in vitro. B) 
C459S reporter had no FRET change with PDGFRβ kinase incubation in vitro. C) R465E 
reporter had FRET change with PDGFRβ kinase incubation in vitro. D) R465E reporter 
had similar level of FRET change with Src kinase incubation in vitro as WT reporter did. 
E) R465E reporter showed increased FRET level upon PDGF stimulation in different 
MEFs (grey dots) with the average shown in solid black line. (mean±s.e.m.).  
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Figure 3.6 A) The phosphorylation of diluted WT reporter before and after phosphatase 
assay. B) The phosphorylation of Y580F reporter with or without Src kinase. C) 
R138LΔ580 reporter had similar increase of phosphatase activity after incubation with 
Src as R138LY580F did. *, p < 0.05. D) R32LY542F had similar FRET increase as WT 
reporter did with Src kinase incubation. 
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Figure 3.7 A) The phosphorylation of C459S reporter before and after PDGFRβ kinase 
incubation. B) The FRET response of WT reporter after addition of PDGFRβ (0min) and 
later 10mM EDTA (180min). C) The phosphorylation of WT reporter with PDGFRβ 
(0min) and EDTA (180min) addition. D) The phosphorylation of R138L reporter with or 
without NSC87877 inhibitor.  
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Chapter 4 
Conclusions 
 
We have employed FRET-based reporter to study the intramolecular interactions and activation 
mechanisms of Shp2. We have observed intramolecular interactions between C-SH2 and 
phosphorylated Y580 (pY580) in WT reporter in vitro. When pY580 is absent, C-SH2 can also 
bind to phosphorylated Y542 (pY542) with a weak FRET change due to the flexible linker 
between pY542 and FRET acceptor YPet. The FRET change of C-SH2 and pY542 binding can 
be amplified and verified by shortening the linker. However, Y580 sequence at the 542 position 
showed no obvious binding to C-SH2 upon phosphorylation with the same shortened linker. 
Therefore we deducted that Y542 sequence is a better substrate to C-SH2 than Y580 sequence. 
Because in WT reporter C-SH2 binds to pY580 other than pY542, we further deducted that 
position 580 is a better position for binding to C-SH2 than position 542. Generally, position of a 
phosphotyrosine is not a crucial factor for intermolecular interactions. However, for 
intramolecular interactions, the relative positions of the two binding partners may be critical for 
the interaction. We suspected that the advantage position of Y580 is from its longer linker 
between phosphatase domain and Y580. From the in vitro studies with FRET as readout, we 
have discovered the intrinsic properties of the two major tyrosine sites in the C-terminal tail of 
Shp2 in terms of their binding ability to C-SH2 and have categorized the properties based on 
either their primary sequences or their positions in the protein. Notably, all the properties are 
embedded in the primary sequence of Shp2 protein.  
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The application of our Shp2 reporters in mouse embryonic fibroblasts showed for the first time 
that intramolecular interaction occurs in live cells upon PDGF stimulation. Surprisingly, the 
intramolecular interaction is distinct from that in vitro with C-SH2 and pY542 as the binding 
pair. Our additional investigation showed that the preference of Y542 sequence by limited 
PDGFR in cells leads to the earlier phosphorylation of Y542. Excess active PDGFR in vitro can 
overcome the adverse Y580 sequence and phosphorylate Y580 efficiently. The phosphorylated 
Y542 then binds to C-SH2 as the phosphorylation of Y580 is not present. This intramolecular 
interaction is necessary for sufficient phosphorylation of Y580 presumably through the 
conformational change of the reporter. The assisted Y580 phosphorylation enables its binding to 
other molecules in cells, e.g. Grb2, which is not present in vitro. The binding of pY580 to Grb2 
prevents pY580 from replacing the binding of pY542 to C-SH2. The different environments in 
vitro and in cells caused the distinct intramolecular interactions of Shp2 reporter. Therefore, we 
concluded that environmental factors can tune the intramolecular interactions of Shp2 reporter. 
 
A closer look at the tunable intramolecular interactions revealed that the counter-balance effects 
of sequence and position between Y542 and Y580 is the key to the tunability. We coupled the 
advantage Y580 position with the preferred Y542 sequence by exchanging the primary 
sequences around Y542 and Y580 to create the SWAP reporter. SWAP reporter showed fixed 
intramolecular interactions between C-SH2 and relocated Y542 at Y580 position both in vitro 
and in cells. In addition, Y580 phosphorylation was impaired in SWAP reporters compared to 
WT reporters suggesting that C-SH2 and pY542 interaction is an important regulatory 
mechanism for sufficient Y580 phosphorylation, which may be an effector for downstream 
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signaling. Indeed, sustained Erk phosphorylation downstream of Shp2 was reduced in SWAP 
compared to WT reporters while the transient Erk phosphorylation was unaltered.  
 
We have shown biological significance of intramolecular interaction between C-SH2 and pY542 
in cells is for sufficient Y580 phosphorylation and subsequent Erk phosphorylation. Another 
significant and more direct effect of C-SH2 and pY542 is to activate phosphatase. Phosphatase 
activity assay results indicated that C-SH2 and pY542 interaction can increase the phosphatase 
activity of Shp2. Even though N-SH2 engagement can already activate Shp2, this additional 
mechanism may be able to either further increase phosphatase activity or sustain the activated 
conformation of Shp2, which can be of physiological significance in cells. However, we found 
that C-SH2 and pY580 interaction doesn’t change phosphatase activity, which is possible 
because C-SH2 domain doesn’t directly interact with phosphatase domain. Since this pair is not 
likely to occur in cell, this may not affect cellular functions.  
 
Our C-SH2 binding to pY580 observed by FRET in vitro agrees with previous chemical study of 
Shp2 phosphorylation using non-hydrolysable phosphate mimics. However, we were not able to 
observe N-SH2 dependent intramolecular interactions by FRET as proposed by the same study. 
So we used an alternative assay by looking at the phosphatase activity. Phosphatase activity 
assay results showed that in the absent of C-SH2, N-SH2 can interaction with either pY542 or 
pY580 which can increase the phosphatase activity. The phosphatase activation through the 
engagement of N-SH2 domain is consistent with the autoinhibition model in which N-SH2 
domain directly interacts with phosphatase domain and blocks the active sites. Therefore 
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phosphatase activity assay can verify the pairing between N-SH2 domain and phosphotyrosines. 
Among the two possible reasons for undetectable N-SH2 domain interactions by FRET, it is 
more likely that N-SH2 domain interaction with phosphotyrosines is not favorable and therefore 
very few phosphorylated reporters adopt this conformation. With low background in phosphatase 
assay, these few reporters with much higher activities can be distinguished. However, the few 
reporters with higher FRET level can be masked by the majority of the reporters with high basal 
line FRET level. Another possibility is that N-SH2 domain binding doesn’t change its FRET 
level. Our current methods cannot distinguish these possibilities, so further efforts using 
computational modeling may help shed the light on the problem. Further studies can also verify 
the sequence-dependent affinity of phosphopeptides towards C-SH2. Currently, our data of 
sequence-dependent affinity is from FRET study. The direct measurement and comparison of 
affinity between C-SH2 and phosphopeptides matching that the sequences surrounding Y542 and 
Y580 by surface plasma resonance can provide another line of evidence for our conclusions. 
 
We have summarized our findings with a circuit model, which can accommodate all the factors 
that affects the intramolecular interactions. The model integrated basic sequence/position-
dependent components with environmental inputs as an analogy to the electric circuit network. 
Circuits have also been used to describe the complex signaling networks by system and synthetic 
biologists. Our molecular circuit can be used to describe molecules in these complex signaling 
networks. Therefore, the circuit-in-circuit representation can be generalized as a tool for system 
and synthetic biologists to describe and design molecular and network circuits, which can be 
added to the current efforts of standardization of biological parts. In addition, our discovery of 
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the basis of tunability can be a general principle for designing tunable molecular circuits or even 
network circuits and pave the way for designing synthetic systems with desired functions. 
 
